242 results on '"van Eycken, E."'
Search Results
2. Time trends of short-term mortality for octogenarians undergoing a colorectal resection in North Europe
- Author
-
Claassen, Y.H.M., Bastiaannet, E., van Eycken, E., Van Damme, N., Martling, A., Johansson, R., Iversen, L.H., Ingeholm, P., Lemmens, V.E.P.P., Liefers, G.J., Holman, F.A., Dekker, J.W.T., Portielje, J.E.A., Rutten, H.J., and van de Velde, C.J.H.
- Published
- 2019
- Full Text
- View/download PDF
3. North European comparison of treatment strategy and survival in older patients with resectable gastric cancer: A EURECCA upper gastrointestinal group analysis
- Author
-
Claassen, Y.H.M., Dikken, J.L., Hartgrink, H.H., de Steur, W.O., Slingerland, M., Verhoeven, R.H.A., van Eycken, E., de Schutter, H., Johansson, J., Rouvelas, I., Johnson, E., Hjortland, G.O., Jensen, L.S., Larsson, H.J., Allum, W.H., Portielje, J.E.A., Bastiaannet, E., and van de Velde, C.J.H.
- Published
- 2018
- Full Text
- View/download PDF
4. Trends in incidence of thick, thin and in situ melanoma in Europe
- Author
-
Sacchetto, L., Zanetti, R., Comber, H., Bouchardy, C., Brewster, D.H., Broganelli, P., Chirlaque, M.D., Coza, D., Galceran, J., Gavin, A., Hackl, M., Katalinic, A., Larønningen, S., Louwman, M.W.J., Morgan, E., Robsahm, T.E., Sanchez, M.J., Tryggvadóttir, L., Tumino, R., Van Eycken, E., Vernon, S., Zadnik, V., and Rosso, S.
- Published
- 2018
- Full Text
- View/download PDF
5. Differences in Treatment and Outcome of Pancreatic Adenocarcinoma Stage I and II in the EURECCA Pancreas Consortium
- Author
-
Groen, J. V., Sibinga Mulder, B. G., van Eycken, E., Valerianova, Z., Borras, J. M., van der Geest, L. G. M., Capretti, G., Schlesinger-Raab, A., Primic-Zakelj, M., Ryzhov, A., van de Velde, C. J. H., Bonsing, B. A., Bastiaannet, E., and Mieog, J. S. D.
- Published
- 2018
- Full Text
- View/download PDF
6. Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: A EUROCARE-5 study
- Author
-
Hackl, M., Zielonke, N., Van Eycken, E., Henau, K., Valerianova, Z., Dimitrova, N., Sekerija, M., Dušek, L., Zvolský, M., Mägi, M., Aareleid, T., Malila, N., Seppä, K., Bouvier, A.M., Faivre, J., Bossard, N., Uhry, Z., Colonna, M., Stabenow, R., Luttmann, S., Eberle, A., Brenner, H., Nennecke, A., Engel, J., Schubert-Fritschle, G., Heidrich, J., Holleczek, B., Katalinic, A., Clough-Gorr, K., Mazzoleni, G., Bulatko, A., Buzzoni, C., Giacomin, A., Ferretti, S., Barchielli, A., Caldarella, A., Gatta, G., Sant, M., Amash, H., Amati, C., Baili, P., Berrino, F., Bonfarnuzzo, S., Botta, L., Capocaccia, R., Di Salvo, F., Foschi, R., Margutti, C., Meneghini, E., Minicozzi, P., Trama, A., Serraino, D., Maso, L. Dal, De Angelis, R., Caldora, M., Carrani, E., Francisci, S., Knijn, A., Mallone, S., Pierannunzio, D., Roazzi, P., Rossi, S., Santaquilani, M., Tavilla, A., Pannozzo, F., Natali, M., Filiberti, R.A., Marani, E., Autelitano, M., Spagnoli, G., Cirilli, C., Fusco, M., Vitale, M.F., Traina, A., Staiti, R., Vitale, F., Cusimano, R., Michiara, M., Tumino, R., Falcini, F., Caiazzo, A.L., Maspero, S., Fanetti, A.C., Zanetti, R., Rosso, S., Rugge, M., Tognazzo, S., Pildava, S., Smailyte, G., Johannesen, T.B., Rachtan, J., Góźdź, S., Mężyk, R., Błaszczyk, J., Kępska, K., Bielska-Lasota, M., Forjaz de Lacerda, G., Bento, M.J., Antunes, L., Miranda, A., Mayer-da-Silva, A., Safaei Diba, C., Primic-Zakelj, M., Almar, E., Mateos, A., Lopez de Munain, A., Larrañaga, N., Torrella-Ramos, A., Díaz García, J.M., Jimenez-Chillaron, R., Marcos-Gragera, R., Vilardell, L., Moreno-Iribas, C., Ardanaz, E., Lambe, M., Mousavi, M., Bouchardy, C., Usel, M., Ess, S.M., Frick, H., Lorez, M., Herrmann, C., Bordoni, A., Spitale, A., Konzelmann, I., Visser, O., Damhuis, R., Otter, R., Coleman, M., Allemani, C., Rachet, B., Rashbass, J., Broggio, J., Verne, J., Gavin, A., Fitzpatrick, D., Huws, D.W., White, C., Minicozzi, Pamela, Innos, Kaire, Sánchez, Maria-José, Trama, Annalisa, Walsh, Paul M., Marcos-Gragera, Rafael, Dimitrova, Nadya, Botta, Laura, Visser, Otto, Rossi, Silvia, Tavilla, Andrea, and Sant, Milena
- Published
- 2017
- Full Text
- View/download PDF
7. Geographical variability in survival of European children with central nervous system tumours
- Author
-
Hackl, M., Zielonke, N., Oberaigner, W., Van Eycken, E., Henau, K., Valerianova, Z., Dimitrova, N., Sekerija, M., Storm, H., Engholm, G., Mägi, M., Aareleid, T., Malila, N., Seppä, K., Faivre, J., Bossard, N., Uhry, Z., Colonna, M., Clavel, J., Lacour, B., Desandes, E., Brenner, H., Kaatsch, P., Katalinic, A., Garami, M., Jakab, Z., Comber, H., Mazzoleni, G., Bulatko, A., Buzzoni, C., Giacomin, A., Sutera Sardo, A., Mancuso, P., Ferretti, S., Barchielli, A., Caldarella, A., Gatta, G., Sant, M., Amash, H., Amati, C., Baili, P., Berrino, F., Bonfarnuzzo, S., Botta, L., Capocaccia, R., Di Salvo, F., Foschi, R., Margutti, C., Meneghini, E., Minicozzi, P., Trama, A., Serraino, D., Zucchetto, A., De Angelis, R., Caldora, M., Carrani, E., Francisci, S., Mallone, S., Pierannunzio, D., Roazzi, P., Rossi, S., Santaquilani, M., Tavilla, A., Pannozzo, F., Busco, S., Filiberti, R.A., Marani, E., Ricci, P., Pascucci, C., Autelitano, M., Spagnoli, G., Cirilli, C., Fusco, M., Vitale, M.F., Usala, M., Vitale, F., Ravazzolo, B., Michiara, M., Merletti, F., Maule, M., Tumino, R., Mangone, L., Di Felice, E., Falcini, F., Iannelli, A., Sechi, O., Cesaraccio, R., Piffer, S., Madeddu, A., Tisano, F., Maspero, S., Fanetti, A.C., Candela, P., Scuderi, T., Stracci, F., Bianconi, F., Tagliabue, G., Contiero, P., Rugge, M., Guzzinati, S., Pildava, S., Smailyte, G., Calleja, N., Agius, D., Johannesen, T.B., Rachtan, J., Góźdź, S., Mężyk, R., Błaszczyk, J., Bębenek, M., Bielska-Lasota, M., Forjaz de Lacerda, G., Bento, M.J., Castro, C., Miranda, A., Mayer-da-Silva, A., Safaei Diba, C., Primic-Zakelj, M., Errezola, M., Bidaurrazaga, J., Vicente Raneda, M., Díaz García, J.M., Marcos-Navarro, A.I., Marcos-Gragera, R., Izquierdo Font, A., Sanchez, M.J., Chang, D.Y.L., Navarro, C., Chirlaque, M.D., Moreno-Iribas, C., Ardanaz, E., Peris-Bonet, R., Pardo Romaguera, E., Galceran, J., Carulla, M., Lambe, M., Mousavi, M., Bouchardy, C., Usel, M., Ess, S.M., Frick, H., Lorez, M., Herrmann, C., Bordoni, A., Spitale, A., Konzelmann, I., Visser, O., Aarts, M., Otter, R., Coleman, M., Allemani, C., Rachet, B., Verne, J., Stiller, C., Gavin, A., Donnelly, C., Brewster, D.H., Sánchez, M.-J., and Rutkowski, S.
- Published
- 2017
- Full Text
- View/download PDF
8. Survival of 86,690 patients with thyroid cancer: A population-based study in 29 European countries from EUROCARE-5
- Author
-
Hackl, M., Zielonke, N., Van Eycken, E., Henau, K., Valerianova, Z., Dimitrova, N., Sekerija, M., Dušek, L., Zvolský, M., Storm, H., Engholm, G., Mägi, M., Aareleid, T., Malila, N., Seppä, K., Velten, M., Guizard, A.V., Faivre, J., Woronoff, A.S., Tretarre, B., Bossard, N., Uhry, Z., Colonna, M., Molinié, F., Bara, S., Schvartz, C., Lapôtre-Ledoux, B., Grosclaude, P., Stabenow, R., Luttmann, S., Eberle, A., Brenner, H., Nennecke, A., Engel, J., Schubert-Fritschle, G., Heidrich, J., Holleczek, B., Katalinic, A., Jónasson, J.G., Tryggvadóttir, L., Comber, H., Mazzoleni, G., Bulatko, A., Buzzoni, C., Giacomin, A., Sutera Sardo, A., Mazzei, A., Ferretti, S., Barchielli, A., Caldarella, A., Gatta, G., Sant, M., Amash, H., Amati, C., Baili, P., Berrino, F., Bonfarnuzzo, S., Botta, L., Capocaccia, R., Di Salvo, F., Foschi, R., Margutti, C., Meneghini, E., Minicozzi, P., Trama, A., Serraino, D., Zucchetto, A., De Angelis, R., Caldora, M., Carrani, E., Francisci, S., Mallone, S., Pierannunzio, D., Roazzi, P., Rossi, S., Santaquilani, M., Tavilla, A., Pannozzo, F., Busco, S., Filiberti, R.A., Vercelli, M., Ricci, P., Autelitano, M., Spagnoli, G., Cirilli, C., Fusco, M., Vitale, M.F., Usala, M., Vitale, F., Ravazzolo, B., Michiara, M., Tumino, R., Mangone, L., Vicentini, M., Falcini, F., Iannelli, A., Sechi, O., Cesaraccio, R., Piffer, S., Madeddu, A., Tisano, F., Maspero, S., Fanetti, A.C., Zanetti, R., Rosso, S., Candela, P., Scuderi, T., Stracci, F., Rocca, A., Tagliabue, G., Contiero, P., Rugge, M., Tognazzo, S., Pildava, S., Smailyte, G., Calleja, N., Agius, D., Johannesen, T.B., Rachtan, J., Góźdź, S., Mężyk, R., Błaszczyk, J., Bębenek, M., Bielska-Lasota, M., Forjaz de Lacerda, G., Bento, M.J., Castro, C., Miranda, A., Mayer-da-Silva, A., Safaei Diba, C., Primic-Zakelj, M., Errezola, M., Bidaurrazaga, J., Díaz García, J.M., Marcos-Navarro, A.I., Marcos-Gragera, R., Izquierdo Font, A., Sanchez, M.J., Molina, E., Navarro, C., Chirlaque, M.D., Moreno-Iribas, C., Ardanaz, E., Galceran, J., Carulla, M., Lambe, M., Khan, S., Mousavi, M., Bouchardy, C., Usel, M., Ess, S.M., Frick, H., Lorez, M., Herrmann, C., Bordoni, A., Spitale, A., Konzelmann, I., Visser, O., Ho, V., Otter, R., Coleman, M., Allemani, C., Rachet, B., Rashbass, J., Broggio, J., Verne, J., Gavin, A., Donnelly, C., Brewster, D.H., Huws, D.W., White, C., Dal Maso, L., Pacini, F., van Dijk, B.A.C., Larrañaga, N., Rubió-Casadevall, J., Kowalska, A., and Virdone, S.
- Published
- 2017
- Full Text
- View/download PDF
9. Long-term survival and cure fraction estimates for childhood cancer in Europe (EUROCARE-6): results from a population-based study
- Author
-
Botta, L, Gatta, G, Capocaccia, R, Stiller, C, Canete, A, Dal Maso, L, Innos, K, Mihor, A, Erdmann, F, Spix, C, Lacour, B, Marcos-Gragera, R, Murray, D, Rossi, S, Hackl, M, Van Eycken, E, Van Damme, N, Valerianova, Z, Sekerija, M, Scoutellas, V, Demetriou, A, Dusek, L, Krejci, D, Storm, H, Magi, M, Paapsi, K, Malila, N, Pitkaniemi, J, Jooste, V, Clavel, J, Poulalhon, C, Desandes, E, Monnereau, A, Katalinic, A, Petridou, E, Markozannes, G, Garami, M, Birgisson, H, Walsh, P, Mazzoleni, G, Vittadello, F, Cuccaro, F, Galasso, R, Sampietro, G, Rosso, S, Gasparotto, C, Maifredi, G, Ferrante, M, Torrisi, A, Sutera Sardo, A, Gambino, M, Lanzoni, M, Ballotari, P, Giacomazzi, E, Ferretti, S, Caldarella, A, Manneschi, G, Sant, M, Baili, P, Berrino, F, Trama, A, Lillini, R, Bernasconi, A, Bonfarnuzzo, S, Vener, C, Didone, F, Lasalvia, P, Del Monego, G, Buratti, L, Serraino, D, Taborelli, M, De Angelis, R, Demuru, E, Di Benedetto, C, Santaquilani, M, Venanzi, S, Tallon, M, Boni, L, Iacovacci, S, Russo, A, Gervasi, F, Spagnoli, G, Cavalieri d'Oro, L, Fusco, M, Vitale, M, Usala, M, Vitale, F, Michiara, M, Chiranda, G, Sacerdote, C, Maule, M, Cascone, G, Spata, E, Mangone, L, Falcini, F, Cavallo, R, Piras, D, Dinaro, Y, Castaing, M, Fanetti, A, Minerba, S, Candela, G, Scuderi, T, Rizzello, R, Stracci, F, Tagliabue, G, Rugge, M, Brustolin, A, Pildava, S, Smailyte, G, Azzopardi, M, Johannesen, T, Didkowska, J, Wojciechowska, U, Bielska-Lasota, M, Pais, A, Ferreira, A, Bento, M, Miranda, A, Safaei Diba, C, Zadnik, V, Zagar, T, Sanchez-Contador Escudero, C, Franch Sureda, P, Lopez de Munain, A, De-La-Cruz, M, Rojas, M, Aleman, A, Vizcaino, A, Almela, F, Sanvisens, A, Sanchez, M, Chirlaque, M, Sanchez-Gil, A, Guevara, M, Ardanaz, E, Canete-Nieto, A, Peris-Bonet, R, Galceran, J, Carulla, M, Kuehni, C, Redmond, S, Visser, O, Karim-Kos, H, Stevens, S, Gavin, A, Morrison, D, Huws, D, Botta L., Gatta G., Capocaccia R., Stiller C., Canete A., Dal Maso L., Innos K., Mihor A., Erdmann F., Spix C., Lacour B., Marcos-Gragera R., Murray D., Rossi S., Hackl M., Van Eycken E., Van Damme N., Valerianova Z., Sekerija M., Scoutellas V., Demetriou A., Dusek L., Krejci D., Storm H., Magi M., Paapsi K., Malila N., Pitkaniemi J., Jooste V., Clavel J., Poulalhon C., Desandes E., Monnereau A., Katalinic A., Petridou E., Markozannes G., Garami M., Birgisson H., Walsh P. M., Mazzoleni G., Vittadello F., Cuccaro F., Galasso R., Sampietro G., Rosso S., Gasparotto C., Maifredi G., Ferrante M., Torrisi A., Sutera Sardo A., Gambino M. L., Lanzoni M., Ballotari P., Giacomazzi E., Ferretti S., Caldarella A., Manneschi G., Sant M., Baili P., Berrino F., Trama A., Lillini R., Bernasconi A., Bonfarnuzzo S., Vener C., Didone F., Lasalvia P., Del Monego G., Buratti L., Serraino D., Taborelli M., De Angelis R., Demuru E., Di Benedetto C., Santaquilani M., Venanzi S., Tallon M., Boni L., Iacovacci S., Russo A. G., Gervasi F., Spagnoli G., Cavalieri d'Oro L., Fusco M., Vitale M. F., Usala M., Vitale F., Michiara M., Chiranda G., Sacerdote C., Maule M., Cascone G., Spata E., Mangone L., Falcini F., Cavallo R., Piras D., Dinaro Y., Castaing M., Fanetti A. C., Minerba S., Candela G., Scuderi T., Rizzello R. V., Stracci F., Tagliabue G., Rugge M., Brustolin A., Pildava S., Smailyte G., Azzopardi M., Johannesen T. B., Didkowska J., Wojciechowska U., Bielska-Lasota M., Pais A., Ferreira A. M., Bento M. J., Miranda A., Safaei Diba C., Zadnik V., Zagar T., Sanchez-Contador Escudero C., Franch Sureda P., Lopez de Munain A., De-La-Cruz M., Rojas M. D., Aleman A., Vizcaino A., Almela F., Sanvisens A., Sanchez M. J., Chirlaque M. D., Sanchez-Gil A., Guevara M., Ardanaz E., Canete-Nieto A., Peris-Bonet R., Galceran J., Carulla M., Kuehni C., Redmond S., Visser O., Karim-Kos H., Stevens S., Gavin A., Morrison D., Huws D. W., Botta, L, Gatta, G, Capocaccia, R, Stiller, C, Canete, A, Dal Maso, L, Innos, K, Mihor, A, Erdmann, F, Spix, C, Lacour, B, Marcos-Gragera, R, Murray, D, Rossi, S, Hackl, M, Van Eycken, E, Van Damme, N, Valerianova, Z, Sekerija, M, Scoutellas, V, Demetriou, A, Dusek, L, Krejci, D, Storm, H, Magi, M, Paapsi, K, Malila, N, Pitkaniemi, J, Jooste, V, Clavel, J, Poulalhon, C, Desandes, E, Monnereau, A, Katalinic, A, Petridou, E, Markozannes, G, Garami, M, Birgisson, H, Walsh, P, Mazzoleni, G, Vittadello, F, Cuccaro, F, Galasso, R, Sampietro, G, Rosso, S, Gasparotto, C, Maifredi, G, Ferrante, M, Torrisi, A, Sutera Sardo, A, Gambino, M, Lanzoni, M, Ballotari, P, Giacomazzi, E, Ferretti, S, Caldarella, A, Manneschi, G, Sant, M, Baili, P, Berrino, F, Trama, A, Lillini, R, Bernasconi, A, Bonfarnuzzo, S, Vener, C, Didone, F, Lasalvia, P, Del Monego, G, Buratti, L, Serraino, D, Taborelli, M, De Angelis, R, Demuru, E, Di Benedetto, C, Santaquilani, M, Venanzi, S, Tallon, M, Boni, L, Iacovacci, S, Russo, A, Gervasi, F, Spagnoli, G, Cavalieri d'Oro, L, Fusco, M, Vitale, M, Usala, M, Vitale, F, Michiara, M, Chiranda, G, Sacerdote, C, Maule, M, Cascone, G, Spata, E, Mangone, L, Falcini, F, Cavallo, R, Piras, D, Dinaro, Y, Castaing, M, Fanetti, A, Minerba, S, Candela, G, Scuderi, T, Rizzello, R, Stracci, F, Tagliabue, G, Rugge, M, Brustolin, A, Pildava, S, Smailyte, G, Azzopardi, M, Johannesen, T, Didkowska, J, Wojciechowska, U, Bielska-Lasota, M, Pais, A, Ferreira, A, Bento, M, Miranda, A, Safaei Diba, C, Zadnik, V, Zagar, T, Sanchez-Contador Escudero, C, Franch Sureda, P, Lopez de Munain, A, De-La-Cruz, M, Rojas, M, Aleman, A, Vizcaino, A, Almela, F, Sanvisens, A, Sanchez, M, Chirlaque, M, Sanchez-Gil, A, Guevara, M, Ardanaz, E, Canete-Nieto, A, Peris-Bonet, R, Galceran, J, Carulla, M, Kuehni, C, Redmond, S, Visser, O, Karim-Kos, H, Stevens, S, Gavin, A, Morrison, D, Huws, D, Botta L., Gatta G., Capocaccia R., Stiller C., Canete A., Dal Maso L., Innos K., Mihor A., Erdmann F., Spix C., Lacour B., Marcos-Gragera R., Murray D., Rossi S., Hackl M., Van Eycken E., Van Damme N., Valerianova Z., Sekerija M., Scoutellas V., Demetriou A., Dusek L., Krejci D., Storm H., Magi M., Paapsi K., Malila N., Pitkaniemi J., Jooste V., Clavel J., Poulalhon C., Desandes E., Monnereau A., Katalinic A., Petridou E., Markozannes G., Garami M., Birgisson H., Walsh P. M., Mazzoleni G., Vittadello F., Cuccaro F., Galasso R., Sampietro G., Rosso S., Gasparotto C., Maifredi G., Ferrante M., Torrisi A., Sutera Sardo A., Gambino M. L., Lanzoni M., Ballotari P., Giacomazzi E., Ferretti S., Caldarella A., Manneschi G., Sant M., Baili P., Berrino F., Trama A., Lillini R., Bernasconi A., Bonfarnuzzo S., Vener C., Didone F., Lasalvia P., Del Monego G., Buratti L., Serraino D., Taborelli M., De Angelis R., Demuru E., Di Benedetto C., Santaquilani M., Venanzi S., Tallon M., Boni L., Iacovacci S., Russo A. G., Gervasi F., Spagnoli G., Cavalieri d'Oro L., Fusco M., Vitale M. F., Usala M., Vitale F., Michiara M., Chiranda G., Sacerdote C., Maule M., Cascone G., Spata E., Mangone L., Falcini F., Cavallo R., Piras D., Dinaro Y., Castaing M., Fanetti A. C., Minerba S., Candela G., Scuderi T., Rizzello R. V., Stracci F., Tagliabue G., Rugge M., Brustolin A., Pildava S., Smailyte G., Azzopardi M., Johannesen T. B., Didkowska J., Wojciechowska U., Bielska-Lasota M., Pais A., Ferreira A. M., Bento M. J., Miranda A., Safaei Diba C., Zadnik V., Zagar T., Sanchez-Contador Escudero C., Franch Sureda P., Lopez de Munain A., De-La-Cruz M., Rojas M. D., Aleman A., Vizcaino A., Almela F., Sanvisens A., Sanchez M. J., Chirlaque M. D., Sanchez-Gil A., Guevara M., Ardanaz E., Canete-Nieto A., Peris-Bonet R., Galceran J., Carulla M., Kuehni C., Redmond S., Visser O., Karim-Kos H., Stevens S., Gavin A., Morrison D., and Huws D. W.
- Abstract
Background: The EUROCARE-5 study revealed disparities in childhood cancer survival among European countries, giving rise to important initiatives across Europe to reduce the gap. Extending its representativeness through increased coverage of eastern European countries, the EUROCARE-6 study aimed to update survival progress across countries and years of diagnosis and provide new analytical perspectives on estimates of long-term survival and the cured fraction of patients with childhood cancer. Methods: In this population-based study, we analysed 135 847 children (aged 0–14 years) diagnosed during 2000–13 and followed up to the end of 2014, recruited from 80 population-based cancer registries in 31 European countries. We calculated age-adjusted 5-year survival differences by country and over time using period analysis, for all cancers combined and for major cancer types. We applied a variant of standard mixture cure models for survival data to estimate the cure fraction of patients by childhood cancer and to estimate projected 15-year survival. Findings: 5-year survival for all childhood cancer combined in Europe in 2010–14 was 81% (95% CI 81–82), showing an increase of three percentage points compared with 2004–06. Significant progress over time was observed for almost all cancers. Survival remained stable for osteosarcomas, Ewing sarcoma, Burkitt lymphoma, non-Hodgkin lymphomas, and rhabdomyoscarcomas. For all cancers combined, inequalities still persisted among European countries (with age-adjusted 5-year survival ranging from 71% [95% CI 60–79] to 87% [77–93]). The 15-year survival projection for all patients with childhood cancer diagnosed in 2010–13 was 78%. We estimated the yearly long-term mortality rate due to causes other than the diagnosed cancer to be around 2 per 1000 patients for all childhood cancer combined, but to approach zero for retinoblastoma. The cure fraction for patients with childhood cancer increased over time from 74% (95% CI 73–75) in 1998–
- Published
- 2022
10. Adjuvant chemotherapy and relative survival of patients with stage II colon cancer – A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania
- Author
-
Breugom, A.J., Bastiaannet, E., Boelens, P.G., Iversen, L.H., Martling, A., Johansson, R., Evans, T., Lawton, S., O'Brien, K.M., Van Eycken, E., Janciauskiene, R., Liefers, G.J., Cervantes, A., Lemmens, V.E.P.P., and van de Velde, C.J.H.
- Published
- 2016
- Full Text
- View/download PDF
11. Patterns of care for non‐small cell lung cancer patients in Belgium: A population‐based study
- Author
-
Verleye, L., De Gendt, C., Vrijens, F., Schillemans, V., Camberlin, C., Silversmit, G., Stordeur, S., Van Eycken, E., Dubois, C., Robays, J., Wauters, I., and Van Meerbeeck, J. P.
- Published
- 2018
- Full Text
- View/download PDF
12. Quality of pathology reporting is crucial for cancer care and registration: A baseline assessment for breast cancers diagnosed in Belgium in 2008
- Author
-
De Schutter, H., Van Damme, N., Colpaert, C., Galant, C., Lambein, K., Cornelis, A., Neven, P., and Van Eycken, E.
- Published
- 2015
- Full Text
- View/download PDF
13. Evaluation of the quality of the management of cancer of the corpus uteri — Selection of relevant quality indicators and implementation in Belgium
- Author
-
Werbrouck, J., Bouche, G., de Jonge, E., Jacomen, G., D'Hondt, V., Denys, H., Van Limbergen, E., Vandermeersch, B., De Schutter, H., Van Eycken, E., Goffin, F., and Amant, F.
- Published
- 2013
- Full Text
- View/download PDF
14. Clear Improvement in Real-World Chronic Myeloid Leukemia Survival: A Comparison With Randomized Controlled Trials
- Author
-
Vener, C., Rossi, S., Minicozzi, P., Marcos-Gragera, R., Poirel, H. A., Maynadie, M., Troussard, X., Pravettoni, G., De Angelis, R., Sant, M., Hackl, M., Van Eycken, E., Valerianova, Z., Sekerija, M., Pavlou, P., Dusek, L., Storm, H., Magi, M., Innos, K., Malila, N., Pitkaniemi, J., Velten, M., Bouvier, A. M., Jooste, V., Guizard, A. V., Launoy, G., Yonli, S. D., Woronoff, A. S., Nousbaum, J. B., Coureau, G., Monnereau, A., Baldi, I., Hammas, K., Tretarre, B., Colonna, M., Plouvier, S., D'Almeida, T., Molinie, F., Cowppli-Bony, A., Bara, S., Schvartz, C., Defossez, G., Lapotre-Ledoux, B., Grosclaude, P., Luttmann, S., Stabenow, R., Nennecke, A., Kieschke, J., Zeissig, S., Holleczek, B., Katalinic, A., Birgisson, H., Murray, D., Walsh, P. M., Mazzoleni, G., Vittadello, F., Cuccaro, F., Galasso, R., Sampietro, G., Rosso, S., Magoni, M., Ferrante, M., Sardo, A. S., Gambino, M. L., Ballotari, P., Giacomazzi, E., Ferretti, S., Caldarella, A., Manneschi, G., Gatta, G., Baili, P., Berrino, F., Botta, L., Trama, A., Lillini, R., Bernasconi, A., Bonfarnuzzo, S., Didone, F., Lasalvia, P., Del Monego, G., Magri, M. C., Buratti, L., Serraino, D., Dal Maso, L., Capocaccia, R., Demuru, E., Di Benedetto, C., Santaquilani, M., Venanzi, S., Filiberti, R. A., Iacovacci, S., Gennaro, V., Russo, A. G., Spagnoli, G., D'Oro, L. C., Fusco, M., Vitale, M. F., Usala, M., Vitale, F., Michiara, M., Chiranda, G., Cascone, G., Spata, E., Mangone, L., Falcini, F., Cavallo, R., Piras, D., Madeddu, A., Bella, F., Fanetti, A. C., Minerba, S., Candela, G., Scuderi, T., Rizzello, R. V., Stracci, F., Tagliabue, G., Rugge, M., Brustolin, A., Pildava, S., Smailyte, G., Azzopardi, M., Johannesen, T. B., Didkowska, J., Wojciechowska, U., Bielska-Lasota, M., Pais, A., Pontes, J. L., Miranda, A., Diba, C. S., Zadnik, V., Zagar, T., Escudero, C. S. -C., Sureda, P. F., de Munain, A. L., De-La-cruz, M., Rojas, M. D., Aleman, A., Vizcaino, A., Sanchez, M. J., Chirlaque, M. D., Eslava, M. G., Ardanaz, E., Galceran, J., Carulla, M., Bergeron, Y., Bouchardy, C., Mousavi, S. M., Bordoni, A., Visser, O., Rashbass, J., Gavin, A., Morrison, D., and Huws, D. W.
- Subjects
Cancer Research ,Survival ,real-world data ,randomized controlled trials (RCTs) ,tyrosine kinase inhibitor (TKI) ,population-based studies ,Tyrosine kinase inhibitor (TKI) ,Randomized controlled trials (RCTs) ,survival ,Real-world data ,Europe ,Oncology ,cancer registries ,chronic myeloid leukemia (CML) ,Chronic myeloid leukemia (CML) ,Cancer registries ,Population-based studies - Abstract
This study was funded by the Compagnia di San Paolo, the Cariplo Foundation and the European Commission (grant number 801520 HP-JA-2017, Innovative Partnership for Action Against Cancer, iPAAC Joint Action). The sources of the funding played no role in designing the study, collecting, analyzing, or interpreting the data, writing the report, or deciding whether or not to submit the article for publication. This research was (partially) funded by Italian Ministry of Health "Ricerca Corrente" funds. Tyrosine kinase inhibitors (TKIs) have been improving the prognosis of patients with chronic myeloid leukemia (CML), but there are still large differences in survival among European countries. This raises questions on the added value of results from population-based studies, which use real-world data, compared to results of randomized controlled trials (RCTs) involving patients with CML. There are also questions about the extent of the findings on RCTs effectiveness for patients in the general population. We compare survival data extracted from our previous systematic review and meta-analysis of CML RCTs with the latest updated population-based survival data of EUROCARE-6, the widest collaborative study on cancer survival in Europe. The EUROCARE-6 CML survival estimated in patients (15-64 years) diagnosed in 2000-2006 vs. 2007-2013 revealed that the prognostic improvement highlighted by RCTs was confirmed in real-world settings, too. The study shows, evaluating for the first time all European regions, that the optimal outcome figures obtained in controlled settings for CML are also achievable (and indeed achieved) in real-world settings with prompt introduction of TKIs in daily clinical practice. However, some differences still persist, particularly in Eastern European countries, where overall survival values are lower than elsewhere, probably due to a delayed introduction of TKIs. Our results suggest an insufficient adoption of adequate protocols in daily clinical practice in those countries where CML survival values remain lower in real life than the values obtained in RCTs. New high-resolution population-based studies may help to identify failures in the clinical pathways followed there.
- Published
- 2022
15. Prognoses for head and neck cancers in Europe diagnosed in 1995–1999: a population-based study
- Author
-
Zigon, G., Berrino, F., Gatta, G., Sánchez, M.-J., van Dijk, B., Van Eycken, E., and Francisci, S.
- Published
- 2011
- Full Text
- View/download PDF
16. Response to the Comment by Suijkerbuijk et al. ‘Survival of stage IV melanoma in Belgium and the Netherlands’
- Author
-
Reyn, B., primary, Van Eycken, E., additional, Louwman, M., additional, Henau, K., additional, Schreuder, K., additional, Brochez, L., additional, Garmyn, M., additional, and Kukutsch, N.A., additional
- Published
- 2021
- Full Text
- View/download PDF
17. P14.22 Quality indicators in neuro-oncology: modified Delphi process for the development of a quality indicator set for assessment of glioma care
- Author
-
Vanhauwaert, D J, primary, Pinson, H, additional, De Schutter, H, additional, Van Eycken, E, additional, De Vleeschouwer, S, additional, and Boterberg, T, additional
- Published
- 2021
- Full Text
- View/download PDF
18. Quality indicators for oesophageal and gastric cancer: a population-based study in Belgium, 2004–2008
- Author
-
STORDEUR, S., VLAYEN, J., VRIJENS, F., CAMBERLIN, C., DE GENDT, C., VAN EYCKEN, E., and LERUT, T.
- Published
- 2015
- Full Text
- View/download PDF
19. Assessment of potential process quality indicators for systemic treatment of breast cancer in Belgium: a population-based study.
- Author
-
UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'oncologie médicale, van Walle, L, Punie, K, Van Eycken, E, de Azambuja, E, Wildiers, H, Duhoux, F P, Vuylsteke, Peter, Barbeaux, A, Van Damme, N, Verhoeven, D, UCL - SSS/IREC/MONT - Pôle Mont Godinne, UCL - (MGD) Service d'oncologie médicale, van Walle, L, Punie, K, Van Eycken, E, de Azambuja, E, Wildiers, H, Duhoux, F P, Vuylsteke, Peter, Barbeaux, A, Van Damme, N, and Verhoeven, D
- Abstract
Quality indicators (QIs) for the management of breast cancer (BC) have been published in Europe and internationally. In Belgium, a task force was established to select measurable process indicators of systemic treatment for BC, focusing on appropriateness of delivered care. The objective of this study was to evaluate the results of the selected QIs, both nationally and among individual centres. Female Belgian residents with unilateral primary invasive BC diagnosed between 2010 and 2014 were selected from the Belgian Cancer Registry database. The national number enabled linkage with the national reimbursement database, which contains information on all reimbursed medical procedures. A total of 12 process indicators were measured on the population and hospital level. Intercentre variability was assessed by median results and interquartile ranges. A total of 48 872 patients were included in the study. QIs concerning specific BC subtypes only applied to patients diagnosed in 2014 (n = 9855). Clinical stage (cStage) I patients (n = 17 116) were staged with positron emission tomography/computed tomography. Among patients who were pT1aN0 human epidermal growth factor receptor 2 (HER2) positive (n = 47), 25.5% (n = 12) received adjuvant trastuzumab. Among patients with de novo metastatic luminal A/B-like HER2-negative BC (n = 295), 17.3% (n = 51) received upfront chemotherapy. (Neo)adjuvant chemotherapy was administered in 52.4% (n = 12 592) of operated women with cStage I-III, in 37.0% (n = 1270) of operated women with cStage I-III luminal A/B-like HER2-negative BC, and in 19.1% of operated women with cStage I luminal A/B-like HER2-negative BC. In the population of operated patients with cStage I-III, of those younger than 70 years that started adjuvant endocrine therapy (n = 3591), 81.7% (n = 2932) continued treatment for ≥4.5 years. Among patients in cStage I-III older than 70 years (n = 8544), 19.0% (n = 1622) received (neo)adjuvant chemotherapy, whereas among patients
- Published
- 2021
20. Effect of hospital volume on quality of care and outcome after rectal cancer surgery
- Author
-
Leonard, D., Penninckx, F., Kartheuser, A., Laenen, A., Van Eycken, E., Bertrand, C., De Coninck, D., Duinslaeger, M., Van de Stadt, J., Vaneerdeweg, W., Claeys, D., Burnon, D., Haustermans, K., Scalliet, P., Spaas, P., Demetter, P., Jouret-Mourin, A., Sempoux, C., Demey, W., Humblet, Y., Van Cutsem, E., Laurent, S., Van Laethem, J. L., Op de Beeck, B., Smeets, P., Melange, M., Rahier, J., Cabooter, M., Pattyn, P., Peeters, M., Buset, M., Mansvelt, B., Vindevoghel, K., Daubie, M., and Thijs, A.
- Published
- 2014
- Full Text
- View/download PDF
21. Incidence and survival of cutaneous melanoma in Belgium and the Netherlands from 2004 to 2016: striking differences and similarities of two neighbouring countries
- Author
-
Reyn, B., primary, Van Eycken, E., additional, Louwman, M., additional, Henau, K., additional, Schreuder, K., additional, Brochez, L., additional, Garmyn, M., additional, and Kukutsch, N.A., additional
- Published
- 2021
- Full Text
- View/download PDF
22. Treatment and Survival of Elderly Patients with Stage I–II Pancreatic Cancer: A Report of the EURECCA Pancreas Consortium
- Author
-
Groen, J.V. (Jesse V.), Douwes, T.A. (Tom A.), van Eycken, E. (Elizabeth), van der Geest, L.G.M. (Lydia G.M.), Johannesen, T.B. (Tom B.), Besselink, M.G. (Marc), Koerkamp, B.G. (Bas Groot), Wilmink, J.W. (Johanna), Bonsing, B.A. (Bert), Portielje, J.E.A. (Johanna E. A.), van de Velde, C.J.H. (Cornelus J. H.), Bastiaannet, E. (Esther), Mieog, J.S.D. (Sven), Groen, J.V. (Jesse V.), Douwes, T.A. (Tom A.), van Eycken, E. (Elizabeth), van der Geest, L.G.M. (Lydia G.M.), Johannesen, T.B. (Tom B.), Besselink, M.G. (Marc), Koerkamp, B.G. (Bas Groot), Wilmink, J.W. (Johanna), Bonsing, B.A. (Bert), Portielje, J.E.A. (Johanna E. A.), van de Velde, C.J.H. (Cornelus J. H.), Bastiaannet, E. (Esther), and Mieog, J.S.D. (Sven)
- Abstract
Background: Elderly patients with pancreatic cancer are underrepresented in clinical trials, resulting in a lack of evidence. Objective: The aim of this study was to compare treatment and overall survival (OS) of patients aged ≥ 70 years with stage I–II pancreatic cancer in the EURECCA Pancreas Consortium. Methods: This was an observational cohort study of the Belgian (BE), Dutch (NL), and Norwegian (NOR) cancer registries. The primary outcome was OS, while secondary outcomes were resection, 90-day mortality after resection, and (neo)adjuvant and palliative chemotherapy. Results: In total, 3624 patients were included. Resection (BE: 50.2%; NL: 36.2%; NOR: 41.3%; p < 0.001), use of (neo)adjuvant chemotherapy (BE: 55.9%; NL: 41.9%; NOR: 13.8%; p < 0.001), palliative chemotherapy (BE: 39.5%; NL: 6.0%; NOR: 15.7%; p < 0.001), and 90-day mortality differed (BE: 11.7%; NL: 8.0%; NOR: 5.2%; p < 0.001). Furthermore, median OS in patients with (BE: 17.4; NL: 15.9; NOR: 25.4 months; p < 0.001) and without resection (BE: 7.0; NL: 3.9; NOR: 6.5 months; p < 0.001) also differed. Conclusions: Differences were observed in treatment and OS in patients aged ≥ 70 years with stage I–II pancreatic cancer, between the population-based cancer registries. Future studies should focus on selection criteria for (non)surgical treatment in older patients so that clinicians can tailor treatment.
- Published
- 2020
- Full Text
- View/download PDF
23. Treatment and Survival of Elderly Patients with Stage I–II Pancreatic Cancer: A Report of the EURECCA Pancreas Consortium
- Author
-
Groen, JV, Douwes, TA, van Eycken, E, van der Geest, LGM, Johannesen, TB, Besselink, MGH, Groot Koerkamp, B, Wilmink, JW, Bonsing, BA, Portielje, JEA, de Velde, Cjhv, Bastiaannet, E, Mieog, JS, Groen, JV, Douwes, TA, van Eycken, E, van der Geest, LGM, Johannesen, TB, Besselink, MGH, Groot Koerkamp, B, Wilmink, JW, Bonsing, BA, Portielje, JEA, de Velde, Cjhv, Bastiaannet, E, and Mieog, JS
- Published
- 2020
24. L’analyse des cancers de l’intervalle dans le dépistage du cancer du sein en Belgique : élaboration de la méthodologie et résultats en Wallonie
- Author
-
Vandenbroucke, A., primary, Goekint, M., additional, Gordower, L., additional, Androgé, C., additional, Haelens, A., additional, Candeur, M., additional, and Van Eycken, E., additional
- Published
- 2013
- Full Text
- View/download PDF
25. Outcome following laparoscopic and open total mesorectal excision for rectal cancer
- Author
-
Penninckx, F., Kartheuser, A., Van de Stadt, J., Pattyn, P., Mansvelt, B., Bertrand, C., Van Eycken, E., Jegou, D., and Fieuws, S.
- Published
- 2013
- Full Text
- View/download PDF
26. Risk adjusted benchmarking of abdominoperineal excision for rectal adenocarcinoma in the context of the Belgian PROCARE improvement project
- Author
-
Penninckx, Freddy, Fieuws, Steffen, Beirens, Koen, Demetter, Pieter, Ceelen, Wim, Kartheuser, Alex, Molle, Gaetan, Van de Stadt, Jean, Vindevoghel, Koen, Van Eycken, Elizabeth, Bertrand, C, De Coninck, D, Duinslaeger, M, Kartheuser, A, Penninckx, F, Van de Stadt, J, Vaneerdeweg, W, Claeys, D, Burnon, D, Haustermans, K, Scalliet, P, Spaas, Ph, Demetter, P, Jouret-Mourin, A, Sempoux, C, Demey, W, Humblet, Y, Van Cutsem, E, Laurent, S, Van Cutsem, E, Van Laethem, JL, Danse, E, de Beeck, B Op, Smeets, P, Melange, M, Rahier, J, Cabooter, M, Pattyn, P, Peeters, M, Buset, M, Haeck, L, Mansvelt, B, Vindevoghel, K, Van Eycken, E, Dercq, J-P, and Thijs, A
- Published
- 2013
- Full Text
- View/download PDF
27. Cancer prevalence estimates in Europe at the beginning of 2000
- Author
-
Gatta, G., Mallone, S., van der Zwan, J. M., Trama, A., Siesling, S., Capocaccia, R., Hackl, M, Van Eycken, E, Henau, K, Hedelin, G, Velten, M, Launoy, G, Guizard, AV, Bouvier, AM, Maynadié, M, Woronoff, A-S, Buemi, A, Colonna, M, Ganry, O, Grosclaude, P, Holleczek, B, Ziegler, H, Tryggvadottir, L, Bellù, F, Ferretti, S, Serraino, D, Dal Maso, L, Bidoli, E, Birri, S, Zucchetto, A, Zainer, L, Vercelli, M, Orengo, MA, Casella, C, Quaglia, A, Federico, M, Rashid, I, Cirilli, C, Fusco, M, Traina, A, Michiara, M, De Lisi, V, Bozzani, F, Giacomin, A, Tumino, R, La Rosa, MG, Spata, E, Signora, A, Mangone, L, Falcini, F, Giorgetti, S, Ravaioli, A, Senatore, G, Iannelli, A, Budroni, M, Piffer, S, Franchini, S, Crocetti, E, Caldarella, A, Intrieri, T, La Rosa, F, Stracci, F, Cassetti, T, Contiero, P, Tagliabue, G, Zambon, P, Guzzinati, S, Berrino, F, Baili, P, Bella, F, Ciampichini, R, Gatta, G, Margutti, C, Micheli, A, Minicozzi, P, Sant, M, Trama, A, Caldora, M, Capocaccia, R, Carrani, E, De Angelis, R, Francisci, S, Grande, E, Inghelmann, R, Lenz, H, Martina, L, Roazzi, P, Santaquilani, M, Simonetti, A, Tavilla, A, Verdecchia, A, Langmark, F, Rachtan, J, Mężyk, R, Góżdź, S., Siudowska, U, Zwierko, M, Bielska-Lasota, M, Safaei Diba, Ch., Primic-Zakelj, M, Mateos, A, Izarzugaza, I, Torrella Ramos, A, Zurriaga, O, Marcos-Gragera, R, Vilardell, ML, Izquierdo, A, Ardanaz, E, Moreno-Iribas, C, Galceran, J, Klint, Å, Talbäck, M, Jundt, G, Usel, M, Frick, H, Ess, SM, Bordoni, A, Konzelmann, I, Dehler, S, Siesling, S, Visser, O, Otter, R, Coebergh, JWW, Greenberg, DC, Wilkinson, J, Roche, M, Verne, J, Meechan, D, Poole, J, Lawrence, G, Gavin, A, Brewster, DH, Black, RJ, and Steward, JA
- Published
- 2013
- Full Text
- View/download PDF
28. 148P Surgery (Sx) of the primary tumour in de novo metastatic breast cancer (BC) patients (pts) is associated with increased survival: A nationwide population-based study by the Belgian Cancer Registry (BCR) and the Belgian Society of Medical Oncology (BSMO)
- Author
-
Brandão, M.D.R.A., primary, de Angelis, C., additional, Vuylsteke, P., additional, Gelber, R.D., additional, Van Damme, N., additional, Van Eycken, E., additional, Verbeeck, J., additional, van Walle, L., additional, Colpaert, C., additional, Lambertini, M., additional, Poggio, F., additional, Verhoeven, D., additional, Barbeaux, A., additional, Duhoux, F.P., additional, Punie, K., additional, Wildiers, H., additional, Caballero, C., additional, Awada, A.H., additional, Piccart, M., additional, and de Azambuja, E., additional
- Published
- 2020
- Full Text
- View/download PDF
29. International comparison of treatment strategy and survival in metastatic gastric cancer
- Author
-
Claassen, Y. H. M., Bastiaannet, E., Hartgrink, H. H., Dikken, J. L., de Steur, W. O., Slingerland, M., Verhoeven, R. H. A., van Eycken, E., de Schutter, H., Lindblad, M., Hedberg, Jakob, Johnson, E., Hjortland, G. O., Jensen, L. S., Larsson, H. J., Koessler, T., Chevallay, M., Allum, W. H., van de Velde, C. J. H., Claassen, Y. H. M., Bastiaannet, E., Hartgrink, H. H., Dikken, J. L., de Steur, W. O., Slingerland, M., Verhoeven, R. H. A., van Eycken, E., de Schutter, H., Lindblad, M., Hedberg, Jakob, Johnson, E., Hjortland, G. O., Jensen, L. S., Larsson, H. J., Koessler, T., Chevallay, M., Allum, W. H., and van de Velde, C. J. H.
- Abstract
BackgroundIn the randomized Asian REGATTA trial, no survival benefit was shown for additional gastrectomy over chemotherapy alone in patients with advanced gastric cancer with a single incurable factor, thereby discouraging surgery for these patients. The purpose of this study was to evaluate treatment strategies for patients with metastatic gastric cancer in daily practice in five European countries, along with relative survival in each country. MethodsNationwide population-based data from Belgium, Denmark, the Netherlands, Norway and Sweden were combined. Patients with primary metastatic gastric cancer diagnosed between 2006 and 2014 were included. The proportion of gastric resections performed and the administration of chemotherapy (irrespective of surgery) within each country were determined. Relative survival according to country was calculated. ResultsOverall, 15 057 patients with gastric cancer were included. The proportion of gastric resections varied from 81 per cent in the Netherlands and Denmark to 183 per cent in Belgium. Administration of chemotherapy was 392 per cent in the Netherlands, compared with 632 per cent in Belgium. The 6-month relative survival rate was between 390 (95 per cent c.i. 378 to 402) per cent in the Netherlands and 541 (521 to 569) per cent in Belgium. ConclusionThere is variation in the use of gastrectomy and chemotherapy in patients with metastatic gastric cancer, and subsequent differences in survival.
- Published
- 2019
- Full Text
- View/download PDF
30. Time trends of short-term mortality for octogenarians undergoing a colorectal resection in North Europe
- Author
-
Claassen, Y. H. M., Claassen, Y. H. M., Bastiaannet, E., van Eycken, E., Van Damme, N., Martling, A., Johansson, R., Iversen, L. H., Ingeholm, P., Lemmens, V. E. P. P., Liefers, G. J., Holman, F. A., Dekker, J. W. T., Portielje, J. E. A., Rutten, H. J., van de Velde, C. J. H., Claassen, Y. H. M., Claassen, Y. H. M., Bastiaannet, E., van Eycken, E., Van Damme, N., Martling, A., Johansson, R., Iversen, L. H., Ingeholm, P., Lemmens, V. E. P. P., Liefers, G. J., Holman, F. A., Dekker, J. W. T., Portielje, J. E. A., Rutten, H. J., and van de Velde, C. J. H.
- Abstract
Background: Decreased cancer specific survival in older colorectal patients is mainly due to mortality in the first year, emphasizing the importance of the first postoperative year. This study aims to gain an overview and time trends of short-term mortality in octogenarians (>= 80 years) with colorectal cancer across four North European countries.Methods: Patients of 80 years or older, operated for colorectal cancer (stage I-Ill) between 2005 and 2014, were included. Population-based cohorts from Belgium, Denmark, the Netherlands, and Sweden were collected. Separately for colon- and rectal cancer, 30-day, 90-day, one-year, and excess one-year mortality were calculated. Also, short-term mortality over three time periods (2005-2008, 2009-2011, 2012-2014) was analyzed.Results: In total, 35,158 colon cancer patients and 10,144 rectal cancer patients were included. For colon cancer, 90-day mortality rate was highest in Denmark (15%) and lowest in Sweden (8%). For rectal cancer, 90-day mortality rate was highest in Belgium (11%) and lowest in Sweden (7%). One-year excess mortality rate of colon cancer patients decreased from 2005 to 2008 to 2012-2014 for all countries (Belgium: 17%-11%, Denmark: 21%-15%, the Netherlands: 18%-10%, and Sweden: 10%-8%). For rectal cancer, from 2005 to 2008 to 2012-2014 one-year excess mortality rate decreased in the Netherlands from 16% to 7% and Sweden: 8%-2%).Conclusions: Short-term mortality rates were high in octogenarians operated for colorectal cancer. Short-term mortality rates differ across four North European countries, but decreased over time for both colon and rectal cancer patients in all countries. (C) 2019 Published by Elsevier Ltd.
- Published
- 2019
31. Head and Neck Cancer in Belgium : Quality of Diagnostic Management and Variability Across Belgian Hospitals Between 2009 and 2014
- Author
-
De Gendt, Cindy, Stordeur, Sabine, Schillemans, Viki, Verleye, Leen, Silversmit, Geert, Van Eycken, E., Savoye, Isabelle, Grégoire, Vincent, Nuyts, Sandra, Vermorken, Jan, Leroy, Roos, De Gendt, Cindy, Stordeur, Sabine, Schillemans, Viki, Verleye, Leen, Silversmit, Geert, Van Eycken, E., Savoye, Isabelle, Grégoire, Vincent, Nuyts, Sandra, Vermorken, Jan, and Leroy, Roos
- Abstract
11 pp., Aims: The study assessed the quality of diagnosis and staging offered to patients with a head and neck squamous cell carcinoma (HNSCC) and the variability across Belgian hospitals. Methods: In total, 9,245 patients diagnosed with HNSCC between 2009 and 2014, were identified in the population-based Belgian Cancer Registry (BCR). The BCR data were coupled with other databases providing information on diagnostic and therapeutic procedures reimbursed by the compulsory health insurance, vital status data, and comorbidities. The use of diagnosis and staging procedures was assessed by four quality indicators (QI) (i.e., use of dedicated head and neck imaging studies, use of PET-CT, TNM reporting and interval between diagnosis and start of treatment), for which a target was defined before the analysis. The association between the binary QIs and observed survival was assessed using Cox proportional hazard models adjusted for potential confounders. Results: Overall, 82.5% of patients received staging by MRI and/or CT of the head and neck region before the start of treatment. In 47.6% of stage III-IV patients eligible for treatment with curative intent, a whole-body FDG-PET(/CT) was performed. The proportion of patients whose cTNM and pTNM stage was reported to the BCR was 80.5 and 78.4%, respectively. The median interval from diagnosis to first treatment with curative intent was 32 days (IQR: 19-46). For none of these QIs the pre-set targets were reached and a substantial variability between centers was observed for all quality indicators. No binary QI was significantly associated with observed survival. Conclusions: The four quality indicators related to diagnosis and staging in HNSCC all showed substantial room for improvement. For none of them the pre-set targets were met at the national level and the variability between centers was substantial. Each Belgian hospital received an individual feedback report in order to stimulate reflection and quality improvement processes.
- Published
- 2019
32. Geographical variability in survival of European children with central nervous system tumours
- Author
-
Storm, H., Engholm, G., Mã¤gi, M., Aareleid, T., Bossard, N., Uhry, Z., Brenner, H., Comber, H., Buzzoni, C., Gatta, G., Sant, M., Amash, H., Amati, C., Baili, P., Berrino, F., Bonfarnuzzo, S., Botta, L., Capocaccia, R., Di Salvo, F., Foschi, R., Margutti, C., Meneghini, E., Minicozzi, P., Trama, A., Tagliabue, G., Contiero, P., Serraino, D., Zucchetto, A., De Angelis, R., Caldora, M., Carrani, E., Francisci, S., Mallone, S., Pierannunzio, D., Roazzi, P., Rossi, S., Santaquilani, M., Tavilla, A., Piffer, S., Calleja, N., Agius, D., Bielska-Lasota, M., Primic-Zakelj, M., Peris-Bonet, R., Pardo Romaguera, E., Lambe, M., Coleman, M., Allemani, C., Rachet, B., Stiller, C., Visser, O., Marcos-Gragera, R., Sã¡nchez, M. -. J., Lacour, B., Kaatsch, P., Rutkowsky, S., Hackl, M., Zielonke, N., Oberaigner, W., Van Eycken, E., Henau, K., Valerianova, Z., Dimitrova, N., Sekerija, M., Malila, N., Seppã¤, K., Faivre, J., Colonna, M., Clavel, J., Desandes, E., Katalinic, A., Garami, M., Jakab, Z., Mazzoleni, G., Bulatko, A., Giacomin, A., Sutera Sardo, A., Mancuso, P., Ferretti, S., Barchielli, A., Caldarella, A., Pannozzo, F., Busco, S., Filiberti, R. A., Marani, E., Ricci, P., Pascucci, C., Autelitano, M., Spagnoli, G., Cirilli, C., Fusco, M., Vitale, M. F., Usala, M., Vitale, F., Ravazzolo, B., Michiara, M., Merletti, F., Maule, M., Tumino, R., Mangone, L., Di Felice, E., Falcini, F., Iannelli, A., Sechi, O., Cesaraccio, R., Madeddu, A., Tisano, F., Maspero, S., Fanetti, A. C., Candela, P., Scuderi, T., Stracci, F., Bianconi, F., Rugge, M., Guzzinati, S., Pildava, S., Smailyte, G., Johannesen, T. B., Rachtan, J., Gã³åºdåº, S., Mężyk, R., BÅ‚aszczyk, J., BÄ™benek, M., Forjaz de Lacerda, G., Bento, M. J., Castro, C., Miranda, A., Mayer-da-Silva, A., Safaei Diba, C., Errezola, M., Bidaurrazaga, J., Vicente Raneda, M., DÃaz GarcÃa, J. M., Marcos-Navarro, A. I., Izquierdo Font, A., Sanchez, M. J., Chang, D. Y. L., Navarro, C., Chirlaque, M. D., Moreno-Iribas, C., Ardanaz, E., Galceran, J., Carulla, M., Mousavi, M., Bouchardy, C., Usel, M., Ess, S. M., Frick, H., Lorez, M., Herrmann, C., Bordoni, A., Spitale, A., Konzelmann, I., Aarts, M., Otter, R., Verne, J., Gavin, A., Donnelly, C., Brewster, D. H., Storm H., Engholm G., Magi M., Aareleid T., Bossard N., Uhry Z., Brenner H., Comber H., Buzzoni C., Gatta G., Sant M., Amash H., Amati C., Baili P., Berrino F., Bonfarnuzzo S., Botta L., Capocaccia R., Di Salvo F., Foschi R., Margutti C., Meneghini E., Minicozzi P., Trama A., Tagliabue G., Contiero P., Serraino D., Zucchetto A., De Angelis R., Caldora M., Carrani E., Francisci S., Mallone S., Pierannunzio D., Roazzi P., Rossi S., Santaquilani M., Tavilla A., Piffer S., Calleja N., Agius D., Bielska-Lasota M., Primic-Zakelj M., Peris-Bonet R., Pardo Romaguera E., Lambe M., Coleman M., Allemani C., Rachet B., Stiller C., Visser O., Marcos-Gragera R., Sanchez M.-J., Lacour B., Kaatsch P., Rutkowsky S., Hackl M., Zielonke N., Oberaigner W., Van Eycken E., Henau K., Valerianova Z., Dimitrova N., Sekerija M., Malila N., Seppa K., Faivre J., Colonna M., Clavel J., Desandes E., Katalinic A., Garami M., Jakab Z., Mazzoleni G., Giacomin A., Sutera Sardo A., Mancuso P., Ferretti S., Barchielli A., Caldarella A., Pannozzo F., Busco S., Filiberti R.A., Marani E., Ricci P., Pascucci C., Autelitano M., Spagnoli G., Cirilli C., Fusco M., Vitale M.F., Usala M., Vitale F., Ravazzolo B., Michiara M., Merletti F., Maule M., Tumino R., Mangone L., Di Felice E., Falcini F., Iannelli A., Sechi O., Cesaraccio R., Madeddu A., Tisano F., Maspero S., Fanetti A.C., Candela P., Scuderi T., Stracci F., Bianconi F., Rugge M., Guzzinati S., Pildava S., Smailyte G., Johannesen T.B., Rachtan J., Gozdz S., Mezyk R., Blaszczyk J., Bebenek M., Forjaz de Lacerda G., Bento M.J., Castro C., Miranda A., Mayer-da-Silva A., Safaei Diba C., Errezola M., Bidaurrazaga J., Vicente Raneda M., Diaz Garcia J.M., Marcos-Navarro A.I., Izquierdo Font A., Sanchez M.J., Chang D.Y.L., Navarro C., Chirlaque M.D., Moreno-Iribas C., Ardanaz E., Galceran J., Carulla M., Mousavi M., Bouchardy C., Usel M., Ess S.M., Frick H., Lorez M., Herrmann C., Bordoni A., Spitale A., Konzelmann I., Aarts M., Otter R., Verne J., Gavin A., Donnelly C., and Brewster D.H.
- Subjects
0301 basic medicine ,Male ,Cancer Research ,Pediatrics ,medicine.medical_specialty ,Childhood cancer survival, Europe, Population-based cancer registries, Disparities, Central nervous system ,Adolescent ,Population ,Population-based cancer registrie ,Socio-culturale ,Disparities ,Central Nervous System Neoplasms ,03 medical and health sciences ,0302 clinical medicine ,Epidemiology of cancer ,Childhood cancer survival ,Medicine ,Humans ,Preschool ,education ,Child ,Grading (tumors) ,Survival rate ,Survival analysis ,education.field_of_study ,business.industry ,Proportional hazards model ,Incidence ,Hazard ratio ,Central Nervous System Neoplasm ,Infant ,Population-based cancer registries ,Disparitie ,Survival Analysis ,Europe ,030104 developmental biology ,Oncology ,Central nervous system ,030220 oncology & carcinogenesis ,Child, Preschool ,Female ,Death certificate ,business ,Human - Abstract
Survival for childhood central nervous system (CNS) tumours varies across Europe, partly because of the difficulty of distinguishing malignant from non-malignant disease. This study examines bias in CNS tumours survival analysis to obtain the reliable and comparable survival figures. We analysed survival data for about 15, 000 children (age
- Published
- 2017
33. International comparison of treatment strategy and survival in metastatic gastric cancer: a survey from the EURECCA Upper GI group
- Author
-
Claassen, Y., primary, Bastiaannet, E., additional, Hartgrink, H., additional, Dikken, J., additional, De Steur, W., additional, Slingerland, M., additional, Verhoeven, R., additional, Van Eycken, E., additional, De Schutter, H., additional, Lindblad, M., additional, Hedberg, J., additional, Johnson, E., additional, Hjortland, G.O., additional, Jensen, L., additional, Larsson, H., additional, Koessler, T., additional, Chevallay, M., additional, Allum, W., additional, and Van de Velde, C., additional
- Published
- 2019
- Full Text
- View/download PDF
34. Oncologic treatment strategies and relative survival of patients with stage I-III rectal cancer - A EURECCA international comparison between the Netherlands, Belgium, Denmark, Sweden, England, Ireland, Spain, and Lithuania
- Author
-
Breugom, A. J., Bastiaannet, E., Boelens, P. G., Van Eycken, E., Iversen, L. H., Martling, A., Johansson, Robert, Evans, T., Lawton, S., O'Brien, K. M., Ortiz, H., Janciauskiene, R., Dekkers, O. M., Rutten, H. J. T., Liefers, G. J., Lemmens, V. E. P. P., van de Velde, C. J. H., Breugom, A. J., Bastiaannet, E., Boelens, P. G., Van Eycken, E., Iversen, L. H., Martling, A., Johansson, Robert, Evans, T., Lawton, S., O'Brien, K. M., Ortiz, H., Janciauskiene, R., Dekkers, O. M., Rutten, H. J. T., Liefers, G. J., Lemmens, V. E. P. P., and van de Velde, C. J. H.
- Abstract
Introduction: The aim of this EURECCA international comparison is to compare oncologic treatment strategies and relative survival of patients with stage I-III rectal cancer between European countries. Material and methods: Population-based national cohort data from the Netherlands (NL), Belgium (BE), Denmark (DK), Sweden (SE), England (ENG), Ireland (IE), Spain (ES), and single-centre data from Lithuania (LT) were obtained. All operated patients with (y)pTNM stage I-III rectal cancer diagnosed between 2004 and 2009 were included. Oncologic treatment strategies and relative survival were calculated and compared between neighbouring countries. Results: We included 57,120 patients. Treatment strategies differed between NL and BE (p < 0.001), DK and SE (p < 0.001), and ENG and IE (p < 0.001). More preoperative radiotherapy as single treatment before surgery was administered in NL compared with BE (59.7% vs. 13.1%), in SE compared with DK (55.1% vs. 10.4%), and in ENG compared with IE (15.2% vs. 9.6%). Less postoperative chemotherapy was given in NL (9.6% vs. 39.1%), in SE (7.9% vs. 14.1%), and in IE (12.6% vs. 18.5%) compared with their neighbouring country. In ES, 55.1% of patients received preoperative chemoradiation and 62.3% post-operative chemotherapy. There were no significant differences in relative survival between neighbouring countries. Conclusion: Large differences in oncologic treatment strategies for patients with (y)pTNM I-III rectal cancer were observed across European countries. No clear relation between oncologic treatment strategies and relative survival was observed. Further research into selection criteria for specific treatments could eventually lead to individualised and optimal treatment for patients with non-metastasised rectal cancer.
- Published
- 2018
- Full Text
- View/download PDF
35. Data quality in rare cancers registraton: The report of the RARECARE data quality study
- Author
-
Trama, A., Marcos-Gragera, R., Perez, M. J. S., van der Zwan, J. M., Ardanaz, E., Bouchardy, C., Melchor, J. M., Martinez, C., Capocaccia, R., Vicentini, M., Siesling, S., Gatta, G., Zielonk, N., Van Eycken, E., Henau, K., Magi, M., Bouvier, A. M., Jooste, V., Faivre, J., Maynadie, M., Manivet, I., Comber, H., Deady, S., Bellu, F., Dal Cappello, T., Ferretti, S., Vercelli, M., Quaglia, A., Federico, M., Cirilli, C., Fusco, M., Michiara, M., Sgargi, P., Giacomin, A., Tumino, R., Cilia, S., Spata, E., Mangone, L., Cinzia, S., Falcini, F., Giorgetti, S., Piffer, S., Franchini, S., Crocetti, E., Caldarella, A., Tagliabue, G., Zambon, P., Fiore, A. R., Dei Tos, A. P., De Angelis, R., England, K., Gozdz, S., Mezyk, R., Zwierko, M., Bielska-Lasota, M., Slowinski, J., Primic-Zakelj, M., Skrlec, F., Mateos, A., Bidaurrazaga, J., Galceran, J., Diaz Garcia, J. M., Martinez-Garcia, C., Sanchez Perez, M. J., Adolfsson, J., Usel, M., Ess, S. M., Spitale, A., Bordoni, A., Konzelmann, I., Visser, O., Otter, R., and Health Technology & Services Research
- Subjects
0301 basic medicine ,Male ,Cancer Research ,medicine.medical_specialty ,media_common.quotation_subject ,Data quality registraton ,Populaton-based cancer registry ,Rare cancers ,Europe ,Female ,Humans ,Neoplasms ,Rare Diseases ,Data Accuracy ,Registries ,03 medical and health sciences ,0302 clinical medicine ,Data accuracy ,medicine ,Medical physics ,Quality (business) ,media_common ,ddc:613 ,Gynecology ,business.industry ,Cancer ,General Medicine ,medicine.disease ,22/4 OA procedure ,030104 developmental biology ,Oncology ,030220 oncology & carcinogenesis ,Data quality ,business - Abstract
Purpose Rare cancers represent 22% of all tumors in Europe; however, the quality of the data of rare cancers may not be as good as the quality of data for common cancer. The project surveillance of rare cancers in Europe (RARECARE) had, among others, the objective of assessing rare cancer data quality in population-based cancer registries (CRs). Eight rare cancers were considered: mesothelioma, liver angiosarcoma, sarcomas, tumors of oral cavity, CNS tumors, germ cell tumors, leukemia, and malignant digestive endocrine tumors. Methods We selected data on 18,000 diagnoses and revised, on the basis of the pathologic and clinical reports (but not on pathologic specimens), unspecified morphology and topography codes originally attributed by CR officers and checked the quality of follow-up of long-term survivors of poor prognosis cancers. Results A total of 38 CRs contributed from 13 European countries. The majority of unspecified morphology and topography cases were confirmed as unspecified. The few unspecified cases that, after the review, changed to a more specific diagnosis increased the incidence of the common cancer histotypes. For example, 11% of the oral cavity epithelial cancers were reclassified from unspecified to more specific diagnoses: 8% were reclassified as squamous cell carcinoma (commoner) and only 1% as adenocarcinoma (rarer). The revision confirmed the majority of long-term survivors revealing a relative high proportion of mesothelioma long-term survivors. The majority of appendix carcinoids changed behavior from malignant to borderline lesions. Conclusions Our study suggests that the problem of poorly specified morphology and topography cases is mainly one of difficulty in reaching a precise diagnosis. The awareness of the importance of data quality for rare cancers should increase among registrars, pathologists, and clinicians.
- Published
- 2017
36. Reasons for low cervical cancer survival in new accession European Union countries: a EUROCARE-5 study.
- Author
-
Bielska-Lasota, Magdalena, Rossi, Silvia, Krzyżak, Michalina, Haelens, Annemie, Domenic, Augius, De Angelis, Roberta, Maciejczyk, Adam, Rodríguez-Barranco, Miguel, Zadnik, Vesna, Minicozzi, Pamela, EUROCARE-5 Working Group, Hackl, M., Ihle, P., Van Eycken, E., Henau, K., Valerianova, Z., Dimitrova, N., Sekerija, M., Cukelj, P., and Dušek, L.
- Subjects
EUROPEAN Union membership ,CERVICAL cancer ,CERVIX uteri diseases ,TUMOR classification ,MEDICAL care ,OLDER women - Abstract
Purpose: With better access to early diagnosis and appropriate treatment, cervical cancer (CC) burden decreased in several European countries. In Eastern European (EE) countries, which accessed European Union in 2004, CC survival was worse than in the rest of Europe. The present study investigates CC survival differences across five European regions, considering stage at diagnosis (local, regional and metastatic), morphology (mainly squamous versus glandular tumours) and patients' age.Methods: We analysed 101,714 CC women diagnosed in 2000-2007 and followed-up to December 2008. Age-standardised 5-year relative survival (RS) and the excess risks of cancer death in the 5 years after diagnosis were computed.Results: EE women were older and less commonly diagnosed with glandular tumours. Proportions of local stage cancers were similar across Europe, while morphology- and stage-specific RS (especially for non-metastatic disease) were lower in Eastern Europe. Adjusting for age and morphology, excess risk of local stage CC death for EE patients remained higher than that for other European women.Conclusion: Stage, age and morphology alone do not explain worse survival in Eastern Europe: less effective care may play a role, probably partly due to fewer or inadequate resources being allocated to health care in this area, compared to the rest of Europe. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
37. International comparison of treatment strategy and survival in metastatic gastric cancer
- Author
-
Claassen, Y. H. M., primary, Bastiaannet, E., additional, Hartgrink, H. H., additional, Dikken, J. L., additional, de Steur, W. O., additional, Slingerland, M., additional, Verhoeven, R. H. A., additional, van Eycken, E., additional, de Schutter, H., additional, Lindblad, M., additional, Hedberg, J., additional, Johnson, E., additional, Hjortland, G. O., additional, Jensen, L. S., additional, Larsson, H. J., additional, Koessler, T., additional, Chevallay, M., additional, Allum, W. H., additional, and van de Velde, C. J. H., additional
- Published
- 2018
- Full Text
- View/download PDF
38. Differences in treatment and outcome of pancreatic adenocarcinoma stage I & II in the EURECCA pancreas consortium
- Author
-
Groen, J.V., primary, van Eycken, E., additional, Valerianova, Z., additional, Borras, J.M., additional, van der Geest, L., additional, Capretti, G., additional, Schlesinger-Raab, A., additional, Primic Žakelj, M., additional, Ryzhov, A., additional, and Mieog, J.S., additional
- Published
- 2018
- Full Text
- View/download PDF
39. Oncologic treatment strategies and relative survival of patients with stage I–III rectal cancer - A EURECCA international comparison between the Netherlands, Belgium, Denmark, Sweden, England, Ireland, Spain, and Lithuania
- Author
-
Breugom, A.J., primary, Bastiaannet, E., additional, Boelens, P.G., additional, Van Eycken, E., additional, Iversen, L.H., additional, Martling, A., additional, Johansson, R., additional, Evans, T., additional, Lawton, S., additional, O'Brien, K.M., additional, Ortiz, H., additional, Janciauskiene, R., additional, Dekkers, O.M., additional, Rutten, H.J.T., additional, Liefers, G.J., additional, Lemmens, V.E.P.P., additional, and van de Velde, C.J.H., additional
- Published
- 2018
- Full Text
- View/download PDF
40. Identification and calculation of quality indicators in systemic treatment in breast cancer
- Author
-
Verhoeven, D., primary, Duhoux, F., additional, De Azambuja, E., additional, Wildiers, H., additional, Vuylsteke, P., additional, Barbeaux, A., additional, Van Damme, N., additional, and Van Eycken, E., additional
- Published
- 2018
- Full Text
- View/download PDF
41. Benodigde ziekenhuiscapaciteit in 2025 en criteria voor aanbodbeheersing van complexe kankerchirurgie, radiotherapie en materniteit : Synthese
- Author
-
Van Den Heede, Koen, Beguin, Claire, Bouckaert, Nicolas, Camberlin, Cécile, De Bekker, Piet, Defourny, Noémie, De Schutter, Harlinde, Devos, Carl, Gerkens, Sophie, Jeurissen, Patrick, Kruse, Florien Margareth, Lefevre, Mélanie, Lievens, Yolande, Mistiaen, Patriek, Vaandering, Aude, Van Eycken, E., van Ginneken, Ewout, Van de Voorde, Carine, Van Den Heede, Koen, Beguin, Claire, Bouckaert, Nicolas, Camberlin, Cécile, De Bekker, Piet, Defourny, Noémie, De Schutter, Harlinde, Devos, Carl, Gerkens, Sophie, Jeurissen, Patrick, Kruse, Florien Margareth, Lefevre, Mélanie, Lievens, Yolande, Mistiaen, Patriek, Vaandering, Aude, Van Eycken, E., van Ginneken, Ewout, and Van de Voorde, Carine
- Abstract
74 p., ill., In het kader van haar plannen voor de hervorming van het ziekenhuislandschap vroeg minister De Block aan het Federaal Kenniscentrum voor de Gezondheidszorg (KCE) om na te gaan hoeveel bedden de Belgische algemene ziekenhuizen in 2025 nodig zullen hebben. Het blijkt dat er vandaag in het algemeen al teveel capaciteit is, en dat deze trend zich zal voortzetten. De grote uitzondering hierop zijn de bedden voor geriatrie en revalidatie, waaraan er nu reeds een tekort is, dat alleen maar zal toenemen. We moeten ook nog veel meer in het dagziekenhuis behandelen dan nu het geval is. Het KCE onderzocht ook de huidige en toekomstige behoeften voor een aantal specifieke types van zorg: de materniteiten, complexe kankerchirurgie en radiotherapie. Operaties bij complexe kankers en radiotherapie zouden enkel nog mogen worden uitgevoerd in een klein aantal ziekenhuizen, met gespecialiseerde expertise, die zo voldoende ervaring kunnen opbouwen en behouden. Hierdoor verhoogt de kans op overleving van de patiënt. Er zijn daarnaast teveel kleine materniteiten die maar 1 of twee bevallingen per dag hebben. Het KCE berekende dat we tegen 2025 een derde van de huidige bedden in de materniteiten kunnen sluiten., VOORWOORD.1 -- SYNTHESE2 -- 1. ACHTERGROND 7 -- 1.1. HUIDIGE SAMENWERKING TUSSEN DE BELGISCHE ZIEKENHUIZEN LEIDT NIET TOT BETERE TAAKVERDELING 7 -- 1.2. NAAR EEN HERVORMING VAN HET ZIEKENHUISLANDSCHAP.8 -- 1.2.1. KCE rapport van 2014: een kader voor een hervormd ziekenhuislandschap 8 -- 1.2.2. Hervormingsplannen van de huidige minister: van ‘Plan van Aanpak’ naar een concrete Conceptnota.8 -- 1.2.3. De rol van programmatie in de huidige ziekenhuishervorming 9 -- 1.2.4. Opdracht van deze studie: berekening benodigde ziekenhuiscapaciteit en bepalen van programmatiecriteria voor een selectie van zorgopdrachten 10 -- 2. CAPACITEITSPLANNING AAN DE HAND VAN EEN TRENDANALYSE.10 -- 2.1. CAPACITEITSPLANNING: AFSTEMMING OP DE BEHOEFTEN VAN DE BEVOLKING IS NODIG10 2.2. CAPACITEITSPLANNING MET BEHULP VAN EEN TRENDANALYSE .11 -- 2.2.1. Trends leren ons wat in het verleden gebeurde en wat we in de toekomst kunnen verwachten 11 -- 2.2.2. ‘Wat als’ scenario’s zijn nodig om opkomende trends en eenmalige veranderingen te vatten 11 -- 3. HUIDIGE TRENDS EN VOORSPELLINGEN VOOR 2025 12 -- 3.1. TRENDANALYSE: DEMOGRAFISCHE EN ANDERE ONTWIKKELINGEN 12 -- 3.2. DE BEVOLKINGSGROEI EN DE VERGRIJZING ZULLEN HET AANTAL KLASSIEKE ZIEKENHUISVERBLIJVEN MET BIJNA 12% DOEN TOENEMEN 13 -- 3.3. GEMIDDELDE VERBLIJFSDUUR BLIJFT VERDER INKRIMPEN 13 -- 3.3.1. Jaarlijkse vermindering met 1,5% of met 1 dag op 10 jaar tijd…13 -- 3.3.2. …voor bijna alle aandoeningen . 13 -- 3.3.3. Een snellere inkorting van de verblijfsduur bij de minder ernstige gevallen 14 -- 3.4. EEN AFNAME VAN HET AANTAL VERPLEEGDAGEN MET 5%, MET EEN VERSCHUIVING VAN ACUTE NAAR CHRONISCHE ZORG 15 -- 3.4.1. Door verblijven in te korten, kan men capaciteit voor een groter aantal verblijven creëren .15 -- 3.4.2. Minder verpleegdagen voor 2 op de 3 pathologiegroepen, met een verschuiving van acute -- naar chronische zorg . 17 -- 3.5. GROTE TOENAME VAN DAGOPNAMES 17 -- 3.6. DEMOGRAFISCHE VERSCHILLEN TUSSEN DE REGIO’S VRAGEN EEN AANGEPASTE BENADE
- Published
- 2017
42. Required hospital capacity in 2025 and criteria for rationalisation of complex cancer surgery, radiotherapy and maternity services : Supplement
- Author
-
Van Den Heede, Koen, Beguin, Claire, Bouckaert, Nicolas, Camberlin, Cécile, De Bekker, Piet, Defourny, Noémie, De Schutter, Harlinde, Devos, Carl, Gerkens, Sophie, Jeurissen, Patrick, Kruse, Florien Margareth, Lefevre, Mélanie, Lievens, Yolande, Mistiaen, Patriek, Vaandering, Aude, Van Eycken, E., van Ginneken, Ewout, Van de Voorde, Carine, Van Den Heede, Koen, Beguin, Claire, Bouckaert, Nicolas, Camberlin, Cécile, De Bekker, Piet, Defourny, Noémie, De Schutter, Harlinde, Devos, Carl, Gerkens, Sophie, Jeurissen, Patrick, Kruse, Florien Margareth, Lefevre, Mélanie, Lievens, Yolande, Mistiaen, Patriek, Vaandering, Aude, Van Eycken, E., van Ginneken, Ewout, and Van de Voorde, Carine
- Abstract
328 p., ill., Accompanying explanation 1 -- MDC PP pre-MDC 2 -- APR-DRG 001 Liver Transplant And/Or Intestinal Transplant 2 -- APR-DRG 002 Heart &/Or Lung Transplant 3 -- APR-DRG 003 Bone Marrow Transplant 4 -- APR-DRG 004 Ecmo Or Tracheostomy With Long Term Mechanical Ventilation With Extensive Procedure or ECMO 5 -- APR-DRG 005 Tracheostomy W Long Term Mechanical Ventilation W/O Extensive Proc 6 -- APR-DRG 006 Pancreas Transplant 7 -- MDC 01 Diseases & disorders of the nervous system 8 -- APR-DRG 020 Craniotomy For Trauma 8 -- APR-DRG 021 Craniotomy Except For Trauma 9 -- APR-DRG 022 Ventricular Shunt Procedures 10 -- APR-DRG 023 Spinal Procedures 11 -- APR-DRG 024 Extracranial Vascular Procedures 12 -- APR-DRG 026 Other Nervous System & Related Procedures 13 -- APR-DRG 040 Spinal Disorders & Injuries 14 -- APR-DRG 041 Nervous System Malignancy 15 -- APR-DRG 042 Degenerative Nervous System Disorders Exc Multiple Sclerosis 16 -- APR-DRG 043 Multiple Sclerosis & Other Demyelinating Diseases 17 -- APR-DRG 044 Intracranial Hemorrhage 18 -- APR-DRG 045 Cerebral Vascular Accident and Precerebral Occlusion with infarct 19 -- APR-DRG 046 Nonspecific Cva & Precerebral Occlusion W/O Infarct 20 -- APR-DRG 047 Transient Ischemia 21 -- APR-DRG 048 Peripheral,Cranial & Autonomic Nerve Disorders 22 -- APR-DRG 049 Bacterial & Tuberculous Infections Of Nervous System 23 -- APR-DRG 050 Non-Bacterial Infections Of Nervous System Exc Viral Meningitis 24 -- APR-DRG 051 Viral Meningitis 25 -- APR-DRG 052 Nontraumatic Stupor & Coma 26 -- APR-DRG 053 Seizure 27 -- APR-DRG 054 Migraine & Other Headaches 28 -- APR-DRG 055 Head Trauma W Coma > 1 Hr Or Hemorrhage 29 -- APR-DRG 056 Brain Contusion/.Laceration & Complicated Skull Fx, Coma < 1Hr Or 30 -- APR-DRG 057 Concussion, Closed Skull Fx Nos, Uncomplicated Intracranial Injury, Coma < 1 Hr Or No Coma 31 -- APR-DRG 058 Other Disorders Of Nervous System 32 -- MDC 02 Diseases & disorders of the eye 33 -- APR-DRG 070 Orbital Procedures 33 -- APR-DRG 073 Eye
- Published
- 2017
43. Capacité hospitalière nécessaire en 2025 et critères de la maîtrise de l’offre pour la chirurgie oncologique complexe, la radiothérapie et la maternité : Synthèse
- Author
-
Van Den Heede, Koen, Beguin, Claire, Bouckaert, Nicolas, Camberlin, Cécile, De Bekker, Piet, Defourny, Noémie, De Schutter, Harlinde, Devos, Carl, Gerkens, Sophie, Jeurissen, Patrick, Kruse, Florien Margareth, Lefevre, Mélanie, Lievens, Yolande, Mistiaen, Patriek, Vaandering, Aude, Van Eycken, E., van Ginneken, Ewout, Van de Voorde, Carine, Van Den Heede, Koen, Beguin, Claire, Bouckaert, Nicolas, Camberlin, Cécile, De Bekker, Piet, Defourny, Noémie, De Schutter, Harlinde, Devos, Carl, Gerkens, Sophie, Jeurissen, Patrick, Kruse, Florien Margareth, Lefevre, Mélanie, Lievens, Yolande, Mistiaen, Patriek, Vaandering, Aude, Van Eycken, E., van Ginneken, Ewout, and Van de Voorde, Carine
- Abstract
74 p., ill., Dans le cadre de ses plans de réforme du paysage hospitalier, la ministre De Block a demandé au Centre fédéral d’Expertise des Soins de Santé (KCE) de calculer le nombre de lits dont nous aurons besoin dans les hôpitaux généraux en 2025. Il semble que nous ayons déjà une capacité trop élevée à l’heure actuelle et que cette situation va encore se marquer davantage dans les années à venir. Quelques exceptions importantes à ce constat : il manque de lits pour les patients gériatriques et la revalidation, et ces déficits vont encore se creuser. Il faut également traiter beaucoup plus de patients en hôpital de jour. Le KCE a également analysé les besoins actuels et à venir pour quelques types de soins spécifiques : les maternités, la chirurgie des cancers complexes et la radiothérapie. Conclusion : les interventions pour cancers complexes et la radiothérapie ne devraient être pratiquées que dans quelques hôpitaux détenant une expertise spécialisée, qui développent et maintiennent une expérience suffisante, car cela augmente les chances de survie pour le patient. Il y a par ailleurs trop de petites maternités où l’on ne pratique que un ou deux accouchements par jour ; le KCE a calculé que l’on devra fermer un tiers des lits actuels de maternité d’ici 2025., PRÉFACE. 1 -- SYNTHÈSE . 2 -- 1. CONTEXTE. 8 -- 1.1. DANS SA FORME ACTUELLE, LA COLLABORATION ENTRE LES HÔPITAUX BELGES N’AMÉLIORE PAS LA RÉPARTITION DES TÂCHES . 8 -- 1.2. VERS UNE RÉFORME DU PAYSAGE HOSPITALIER 9 -- 1.2.1. Rapport 2014 du KCE : un cadre pour une réforme du paysage hospitalier 9 -- 1.2.2. Les projets de réforme de la ministre actuelle : d’un « Plan d’Approche » à une note conceptuelle concrète . 9 -- 1.2.3. Le rôle de la programmation dans la réforme hospitalière actuelle 10 -- 1.2.4. Objectif de la présente étude : évaluer la capacité hospitalière requise et définir les critères de programmation pour un certain nombre de missions de soins 11 -- 2. PLANIFICATION DE LA CAPACITÉ À L’AIDE D’UNE ANALYSE DES TENDANCES 12 -- 2.1. PLANIFICATION DE LA CAPACITÉ EN FONCTION DES BESOINS DE LA POPULATION 12 -- 2.2. PLANIFICATION DE LA CAPACITÉ À L’AIDE D’UNE ANALYSE DES TENDANCES.12 -- 2.2.1. Les tendances nous renseignent sur le passé et nous prédisent ce que l’avenir pourrait nous réserver 12 -- 2.2.2. Des scénarios de type « et si… » sont nécessaires pour cerner les tendances émergentes et les changements ponctuels 13 -- 3. TENDANCES ACTUELLES ET PRÉVISIONS À L’HORIZON 2025 .13 -- 3.1. ANALYSE DES TENDANCES : DÉVELOPPEMENTS DÉMOGRAPHIQUES ET AUTRES .13 -- 3.2. LES HOSPITALISATIONS CLASSIQUES EN HAUSSE DE PRÈS DE 12 % SOUS L’EFFET DE LA CROISSANCE DE LA POPULATION ET DU VIEILLISSEMENT .14 -- 3.3. LA DURÉE DE SÉJOUR CONTINUE À SE RACCOURCIR 15 -- 3.3.1. Une baisse annuelle de 1,5 %, soit 1 jour sur une période de 10 ans…15 -- 3.3.2. … pour presque toutes les pathologies 15 -- 3.3.3. Une baisse plus rapide pour les cas les moins sévères .15 -- 3.4. UNE BAISSE DE 5 % DU NOMBRE DE JOURNÉES D’HOSPITALISATION, AVEC UN GLISSEMENT DES SOINS AIGUS VERS LES SOINS CHRONIQUES 17 -- 3.4.1. Réduire la durée de séjour permet d’accroître la capacité en termes de nombre de séjours 17 -- 3.4.2. Moins de journées d’hospitalisation pour 2/3 des groupes de path
- Published
- 2017
44. Required hospital capacity in 2025 and criteria for rationalisation of complex cancer surgery, radiotherapy and maternity services
- Author
-
Van Den Heede, Koen, Beguin, Claire, Bouckaert, Nicolas, Camberlin, Cécile, De Bekker, Piet, Defourny, Noémie, De Schutter, Harlinde, Devos, Carl, Gerkens, Sophie, Jeurissen, Patrick, Kruse, Florien Margareth, Lefevre, Mélanie, Lievens, Yolande, Mistiaen, Patriek, Vaandering, Aude, Van Eycken, E., van Ginneken, Ewout, Van de Voorde, Carine, Van Den Heede, Koen, Beguin, Claire, Bouckaert, Nicolas, Camberlin, Cécile, De Bekker, Piet, Defourny, Noémie, De Schutter, Harlinde, Devos, Carl, Gerkens, Sophie, Jeurissen, Patrick, Kruse, Florien Margareth, Lefevre, Mélanie, Lievens, Yolande, Mistiaen, Patriek, Vaandering, Aude, Van Eycken, E., van Ginneken, Ewout, and Van de Voorde, Carine
- Abstract
544 p., ill., SCIENTIFIC REPORT 33 -- INTRODUCTION AND BACKGROUND 33 -- 1 PROJECTED FUTURE TRENDS OF HOSPITAL USE IN BELGIUM 35 -- 1.1 INTRODUCTION 35 -- 1.2 TREND ANALYSIS 36 -- 1.3 DATA 37 -- 1.3.1 Population data 37 -- 1.3.2 Hospital data 39 -- 1.4 EVALUATION OF THE REPORT CANNOODT 40 -- 1.4.1 Projection model 41 -- 1.4.2 Comments on the research methodology 45 -- 1.4.3 Evaluation of the projection outcomes 46 -- 1.5 PROJECTION MODEL DEVELOPED FOR THE CURRENT STUDY 59 -- 1.5.1 Defining scope and concepts 61 -- 1.5.2 Rationale for statistical trend analysis 68 -- 1.5.3 Statistical trend model 70 -- 1.5.4 Projection outcomes 78 -- 1.6 INTRODUCTION RESULTS 80 -- 1.7 BASELINE FORECAST RESULTS OF THE PROJECTION MODEL 81 -- 1.7.1 Future need for hospital inpatient care 81 -- 1.7.2 Future need for hospital day care 104 -- 1.7.3 Capacity requirements for isolated categorical hospitals and foreign patients 112 -- 1.7.4 Summary of baseline forecast results 116 -- 1.8 PROJECTION RESULTS SCENARIO WITH ACCELERATED SUBSTITUTION TO DAY CARE 124 -- 1.8.1 Methodology 125 -- 1.8.2 Results 130 -- 1.9 PROJECTION RESULTS SCENARIO WITH ACCELERATED POPULATION AGEING 135 -- 1.9.1 Methodology 135 -- 1.9.2 Results 137 -- 2 HOSPITAL USE BY PATIENTS WITH DEMENTIA 145 -- 2.1 BACKGROUND AND AIM OF THE STUDY 145 -- 2.2 METHOD 147 -- 2.2.1 Literature review 147 -- 2.2.2 Analysis of Belgian hospital registry data 148 -- 2.3 RESULTS ON EPIDEMIOLOGICAL DATA 150 -- 2.3.1 Incidence/prevalence of dementia 150 -- 2.3.2 Hospital use by dementia patients 154 -- 2.4 RESULTS ON INTERVENTIONS TO REDUCE HOSPITAL USE BY DEMENTIA PATIENTS 162 -- 2.4.1 Strategies outside the hospital with an impact on hospital use 162 -- 2.4.2 Strategies in the hospital 164 -- 2.4.3 Strategies with regard to fall prevention 166 -- 2.5 DISCUSSION AND CONCLUSION 166 -- 3 ENGLAND 169 -- 3.1 BACKGROUND 169 -- 3.1.1 Country context 169 -- 3.1.2 Hospital classification 170 -- 3.1.3 Hospital capacity and use 170 -- 3.1.4 English hospitals underwen
- Published
- 2017
45. Adjuvant chemotherapy and relative survival of patients with stage II colon cancer - A EURECCA international comparison between the Netherlands, Denmark, Sweden, England, Ireland, Belgium, and Lithuania
- Author
-
Breugom A, Bastiaannet E, Boelens P, Iversen L, Martling A, Johansson R, Evans T, Lawton S, O'Brien K, Van Eycken E, Janciauskiene R, Liefers G, Cervantes A, Lemmens V, and van de Velde C
- Published
- 2016
46. The advantage of women in cancer survival: An analysis of EUROCARE-4 data
- Author
-
Micheli, A., Ciampichini, R., Oberaigner, W., Ciccolallo, L., de Vries, E., Izarzugaza, I., Zambon, P., Gatta, G., De Angelis, R., Hackl, M., Van Eycken, E., Verstreken, Martine, Holub, J., Jurickova, L., Storm, H. H., Engholm, G., Hakulinen, T., Belot, A., Hedelin, G., Velten, M., Tron, I., Le Gall, E., Launoy, G., Guizard, A. V., Faivre, J., Bouvier, A. M., Carli, P. M., Maynadie, M., Danzon, A., Buemi, A., Tretarre, B., Lacour, B., Desandes, E., Colonna, M., Molinie, F., Bara, S., Schvartz, C., Ganry, O., Grosclaude, P., Brenner, H., Kaatsch, P., Ziegler, H., Tryggvadottir, L., Comber, H., Berrino, F., Allemani, C., Baili, P., Sant, M., Sowe, S., Zigon, G., Tagliabue, G., Contiero, P., Bellu`, F., Giacomin, A., Ferretti, S., Serraino, D., Dal Maso, L., De Dottori, M., D. e. Paoli, A., Zanier, L., Vercelli, M., Orengo, M. A., Casella, C., Quaglia, A., Pannelli, F., Federico, M., Rashid, I., Cirilli, C., Fusco, M., Traina, A., De Lisi, V., Bozzani, F., Magnani, C., Pastore, G., Tumino, R., La Rosa, M. G., Spata, E., Sigona, A., Mangone, L., Falcini, F., Foca, F., Giorgetti, S., Senatore, G., Iannelli, A., Budroni, M., Patriarca, S., Zanetti, R., Rosso, S., Piffer, S., Franchini, S., Paci, E., Crocetti, E., La Rosa, F., Stracci, F., Cassetti, T., Guzzinati, S., Caldora, M., Capocaccia, R., Carrani, E., Francisci, S., Grande, E., Inghelmann, R., Lenz, H., Martina, L., Roazzi, P., Santaquilani, M., Simonetti, A., Tavilla, A., Verdecchia, A., Dalmas, M., Langmark, F., Bray, F., Johannesen, T. B., Rachtan, J., Gozdz, S., Siudowska, U., Mezyk, R., Bielska-Lasota, M., Zwierko, M., Pinheiro, P. S., Primic-Zakelj, M., Mateos, A., Torrella-Ramos, A., Zurriaga, Oscar, Marcos-Gragera, R., Vilardell, M. L., Izquierdo, A., Martinez-Garcia, C., Sanchez, M. J., Navarro, C., Chirlaque, M. D., Peris-Bonet, R., Ardanaz, E., Moreno, C., Galceran, J., Klint, A., Talback, M., Jundt, G., Usel, M., Frick, H., Ess, S. M., Bordoni, A., Luthi, J. C., Konzelmann, I., Probst, N., Lutz, J. M., Pury, P., Visser, O., Otter, R., Schaapveld, M., Coebergh, J. W. W., Janssen-Heijnen, M. L., Louis van der Heijden, Null, Greenberg, D. C., Coleman, M. P., Woods, Laura, Moran, T., Forman, D., Cooper, N., Roche, M., Verne, J., Mã¸ller, H., Meechan, D., Poole, J., Lawrence, G., Stiller, C., Gavin, A., Black, R. J., Brewster, D. H., Steward, J. A., Basque Country Cancer Registry, Vitoria-Gasteiz, Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC ( CEF2P / CARCINO ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Université Bourgogne Franche-Comté ( UBFC ) -Université de Franche-Comté ( UFC ), Carcinogénèse épithéliale : facteurs prédictifs et pronostiques - UFC (EA 3181) (CEF2P / CARCINO), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), and Public Health
- Subjects
Oncology ,Male ,Pathology ,Cancer Research ,cancer survival - women ,MESH : Age Distribution ,MESH : Aged ,MESH: Risk Assessment ,[ SDV.CAN ] Life Sciences [q-bio]/Cancer ,0302 clinical medicine ,MESH: Aged, 80 and over ,Residence Characteristics ,Neoplasms ,80 and over ,Gender differences ,Sex hormones ,MESH: Neoplasms ,MESH : Female ,MESH: Residence Characteristics ,Young adult ,Age of Onset ,MESH : Risk Assessment ,MESH : Sex Distribution ,MESH: Diagnosis-Related Groups ,MESH: Aged ,Aged, 80 and over ,0303 health sciences ,education.field_of_study ,MESH: Middle Aged ,Relative survival ,Thyroid ,MESH: Sex Distribution ,Middle Aged ,MESH : Adult ,3. Good health ,MESH : Age of Onset ,Europe ,MESH : Diagnosis-Related Groups ,medicine.anatomical_structure ,MESH: Young Adult ,030220 oncology & carcinogenesis ,MESH: Survival Analysis ,MESH : Residence Characteristics ,Female ,EUROCARE ,Adult ,medicine.medical_specialty ,Adolescent ,MESH: Age of Onset ,MESH : Male ,MESH : Sex Factors ,Population ,MESH : Europe ,MESH : Young Adult ,Rectum ,Socio-culturale ,[SDV.CAN]Life Sciences [q-bio]/Cancer ,Risk Assessment ,03 medical and health sciences ,Young Adult ,Age Distribution ,Sex Factors ,MESH: Sex Factors ,SDG 3 - Good Health and Well-being ,Internal medicine ,MESH : Adolescent ,medicine ,Humans ,MESH : Middle Aged ,Sex Distribution ,education ,MESH : Aged, 80 and over ,MESH: Age Distribution ,Survival analysis ,Diagnosis-Related Groups ,030304 developmental biology ,Aged ,MESH: Adolescent ,MESH: Humans ,business.industry ,MESH : Humans ,Cancer ,Cancer survival ,Survival Analysis ,MESH: Adult ,medicine.disease ,MESH : Neoplasms ,MESH: Male ,MESH: Europe ,Age of onset ,MESH : Survival Analysis ,business ,MESH: Female - Abstract
We analysed 1.6 million population-based EUROCARE-4 cancer cases (26 cancer sites, excluding sex-specific sites, and breast) from 23 countries to investigate the role of sex in cancer survival according to age at diagnosis, site, and European region. For 15 sites (salivary glands, head and neck, oesophagus, stomach, colon and rectum, pancreas, lung, pleura, bone, melanoma of skin, kidney, brain, thyroid, Hodgkin disease and non-Hodgkin's lymphoma) age- and region-adjusted relative survival was significantly higher in women than men. By multivariable analysis, women had significantly lower relative excess risk (RER) of death for the sites listed above plus multiple myeloma. Women significantly had higher RER of death for biliary tract, bladder and leukaemia. For all cancers combined women had a significant 5% lower RER of death. Age at diagnosis was the main determinant of the women's advantage, which, however, decreased with increasing age, becoming negligible in the elderly, suggesting that sex hormone patterns may have a role in women's superior ability to cope with cancer. (C) 2008 Elsevier Ltd. All rights reserved.
- Published
- 2009
47. Quality analysis of population-based information on cancer stage at diagnosis across Europe, with presentation of stage-specific cancer survival estimates: A EUROCARE-5 study
- Author
-
Minicozzi, Pamela, primary, Innos, Kaire, additional, Sánchez, Maria-José, additional, Trama, Annalisa, additional, Walsh, Paul M., additional, Marcos-Gragera, Rafael, additional, Dimitrova, Nadya, additional, Botta, Laura, additional, Visser, Otto, additional, Rossi, Silvia, additional, Tavilla, Andrea, additional, Sant, Milena, additional, Hackl, M., additional, Zielonke, N., additional, Van Eycken, E., additional, Henau, K., additional, Valerianova, Z., additional, Dimitrova, N., additional, Sekerija, M., additional, Dušek, L., additional, Zvolský, M., additional, Mägi, M., additional, Aareleid, T., additional, Malila, N., additional, Seppä, K., additional, Bouvier, A.M., additional, Faivre, J., additional, Bossard, N., additional, Uhry, Z., additional, Colonna, M., additional, Stabenow, R., additional, Luttmann, S., additional, Eberle, A., additional, Brenner, H., additional, Nennecke, A., additional, Engel, J., additional, Schubert-Fritschle, G., additional, Heidrich, J., additional, Holleczek, B., additional, Katalinic, A., additional, Clough-Gorr, K., additional, Mazzoleni, G., additional, Bulatko, A., additional, Buzzoni, C., additional, Giacomin, A., additional, Ferretti, S., additional, Barchielli, A., additional, Caldarella, A., additional, Gatta, G., additional, Sant, M., additional, Amash, H., additional, Amati, C., additional, Baili, P., additional, Berrino, F., additional, Bonfarnuzzo, S., additional, Botta, L., additional, Capocaccia, R., additional, Di Salvo, F., additional, Foschi, R., additional, Margutti, C., additional, Meneghini, E., additional, Minicozzi, P., additional, Trama, A., additional, Serraino, D., additional, Maso, L. Dal, additional, De Angelis, R., additional, Caldora, M., additional, Carrani, E., additional, Francisci, S., additional, Knijn, A., additional, Mallone, S., additional, Pierannunzio, D., additional, Roazzi, P., additional, Rossi, S., additional, Santaquilani, M., additional, Tavilla, A., additional, Pannozzo, F., additional, Natali, M., additional, Filiberti, R.A., additional, Marani, E., additional, Autelitano, M., additional, Spagnoli, G., additional, Cirilli, C., additional, Fusco, M., additional, Vitale, M.F., additional, Traina, A., additional, Staiti, R., additional, Vitale, F., additional, Cusimano, R., additional, Michiara, M., additional, Tumino, R., additional, Falcini, F., additional, Caiazzo, A.L., additional, Maspero, S., additional, Fanetti, A.C., additional, Zanetti, R., additional, Rosso, S., additional, Rugge, M., additional, Tognazzo, S., additional, Pildava, S., additional, Smailyte, G., additional, Johannesen, T.B., additional, Rachtan, J., additional, Góźdź, S., additional, Mężyk, R., additional, Błaszczyk, J., additional, Kępska, K., additional, Bielska-Lasota, M., additional, Forjaz de Lacerda, G., additional, Bento, M.J., additional, Antunes, L., additional, Miranda, A., additional, Mayer-da-Silva, A., additional, Safaei Diba, C., additional, Primic-Zakelj, M., additional, Almar, E., additional, Mateos, A., additional, Lopez de Munain, A., additional, Larrañaga, N., additional, Torrella-Ramos, A., additional, Díaz García, J.M., additional, Jimenez-Chillaron, R., additional, Marcos-Gragera, R., additional, Vilardell, L., additional, Moreno-Iribas, C., additional, Ardanaz, E., additional, Lambe, M., additional, Mousavi, M., additional, Bouchardy, C., additional, Usel, M., additional, Ess, S.M., additional, Frick, H., additional, Lorez, M., additional, Herrmann, C., additional, Bordoni, A., additional, Spitale, A., additional, Konzelmann, I., additional, Visser, O., additional, Damhuis, R., additional, Otter, R., additional, Coleman, M., additional, Allemani, C., additional, Rachet, B., additional, Rashbass, J., additional, Broggio, J., additional, Verne, J., additional, Gavin, A., additional, Fitzpatrick, D., additional, Huws, D.W., additional, and White, C., additional
- Published
- 2017
- Full Text
- View/download PDF
48. Geographical variability in survival of European children with central nervous system tumours
- Author
-
Gatta, G., primary, Peris-Bonet, R., additional, Visser, O., additional, Stiller, C., additional, Marcos-Gragera, R., additional, Sánchez, M.-J., additional, Lacour, B., additional, Kaatsch, P., additional, Berrino, F., additional, Rutkowski, S., additional, Botta, L., additional, Hackl, M., additional, Zielonke, N., additional, Oberaigner, W., additional, Van Eycken, E., additional, Henau, K., additional, Valerianova, Z., additional, Dimitrova, N., additional, Sekerija, M., additional, Storm, H., additional, Engholm, G., additional, Mägi, M., additional, Aareleid, T., additional, Malila, N., additional, Seppä, K., additional, Faivre, J., additional, Bossard, N., additional, Uhry, Z., additional, Colonna, M., additional, Clavel, J., additional, Desandes, E., additional, Brenner, H., additional, Katalinic, A., additional, Garami, M., additional, Jakab, Z., additional, Comber, H., additional, Mazzoleni, G., additional, Bulatko, A., additional, Buzzoni, C., additional, Giacomin, A., additional, Sutera Sardo, A., additional, Mancuso, P., additional, Ferretti, S., additional, Barchielli, A., additional, Caldarella, A., additional, Gatta, G., additional, Sant, M., additional, Amash, H., additional, Amati, C., additional, Baili, P., additional, Bonfarnuzzo, S., additional, Capocaccia, R., additional, Di Salvo, F., additional, Foschi, R., additional, Margutti, C., additional, Meneghini, E., additional, Minicozzi, P., additional, Trama, A., additional, Serraino, D., additional, Zucchetto, A., additional, De Angelis, R., additional, Caldora, M., additional, Carrani, E., additional, Francisci, S., additional, Mallone, S., additional, Pierannunzio, D., additional, Roazzi, P., additional, Rossi, S., additional, Santaquilani, M., additional, Tavilla, A., additional, Pannozzo, F., additional, Busco, S., additional, Filiberti, R.A., additional, Marani, E., additional, Ricci, P., additional, Pascucci, C., additional, Autelitano, M., additional, Spagnoli, G., additional, Cirilli, C., additional, Fusco, M., additional, Vitale, M.F., additional, Usala, M., additional, Vitale, F., additional, Ravazzolo, B., additional, Michiara, M., additional, Merletti, F., additional, Maule, M., additional, Tumino, R., additional, Mangone, L., additional, Di Felice, E., additional, Falcini, F., additional, Iannelli, A., additional, Sechi, O., additional, Cesaraccio, R., additional, Piffer, S., additional, Madeddu, A., additional, Tisano, F., additional, Maspero, S., additional, Fanetti, A.C., additional, Candela, P., additional, Scuderi, T., additional, Stracci, F., additional, Bianconi, F., additional, Tagliabue, G., additional, Contiero, P., additional, Rugge, M., additional, Guzzinati, S., additional, Pildava, S., additional, Smailyte, G., additional, Calleja, N., additional, Agius, D., additional, Johannesen, T.B., additional, Rachtan, J., additional, Góźdź, S., additional, Mężyk, R., additional, Błaszczyk, J., additional, Bębenek, M., additional, Bielska-Lasota, M., additional, Forjaz de Lacerda, G., additional, Bento, M.J., additional, Castro, C., additional, Miranda, A., additional, Mayer-da-Silva, A., additional, Safaei Diba, C., additional, Primic-Zakelj, M., additional, Errezola, M., additional, Bidaurrazaga, J., additional, Vicente Raneda, M., additional, Díaz García, J.M., additional, Marcos-Navarro, A.I., additional, Izquierdo Font, A., additional, Sanchez, M.J., additional, Chang, D.Y.L., additional, Navarro, C., additional, Chirlaque, M.D., additional, Moreno-Iribas, C., additional, Ardanaz, E., additional, Pardo Romaguera, E., additional, Galceran, J., additional, Carulla, M., additional, Lambe, M., additional, Mousavi, M., additional, Bouchardy, C., additional, Usel, M., additional, Ess, S.M., additional, Frick, H., additional, Lorez, M., additional, Herrmann, C., additional, Bordoni, A., additional, Spitale, A., additional, Konzelmann, I., additional, Aarts, M., additional, Otter, R., additional, Coleman, M., additional, Allemani, C., additional, Rachet, B., additional, Verne, J., additional, Gavin, A., additional, Donnelly, C., additional, and Brewster, D.H., additional
- Published
- 2017
- Full Text
- View/download PDF
49. Morbidity of RALP for PCa with seminal vesicle invasion: Results from the Be-RALP project
- Author
-
Poelaert, F., primary, Joniau, S., additional, Roumeguère, T., additional, Ameye, F., additional, De Coster, G., additional, Dekuyper, P., additional, Quackels, T., additional, Van Cleynenbreugel, B., additional, Van Damme, N., additional, Van Eycken, E., additional, and Lumen, N., additional
- Published
- 2017
- Full Text
- View/download PDF
50. Patterns of care for non-small cell lung cancer patients in Belgium: A population-based study
- Author
-
Verleye, L., primary, De Gendt, C., additional, Vrijens, F., additional, Schillemans, V., additional, Camberlin, C., additional, Silversmit, G., additional, Stordeur, S., additional, Van Eycken, E., additional, Dubois, C., additional, Robays, J., additional, Wauters, I., additional, and Van Meerbeeck, J. P., additional
- Published
- 2017
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.